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Hepatitis E is not well-understood in the United States. Seroprevalence, transmission, 
and subclinical manifestations have either not been studied of been the subject of a 
small number of studies with limited conclusions. The purpose of this dissertation was to 
better understand the role of Hepatitis E in the United States. This dissertation updated 
the seroprevalence estimates in the United States, investigated previous inconsistencies 
in the seroprevalence, identified potential risk factors, and examined a potential for 
subclinical liver abnormalities in persons recently infected. We found seroprevalence in 
the United States has remained stable at 6%. In addition, we found non-Hispanic Asians 
had especially high seroprevalence compared to other demographic groups. We also 
determined the difference between seroprevalence estimates from the 1990s compared 
with modern seroprevalence estimates were largely, but not completely due to 
differences in diagnostic assays. We were unable to find any association between recent 
HEV infection and liver inflammation; however, we found a tenuous relationship between 
past HEV infection and liver fibrosis. While this paper was unable to find risk factors 
suggesting a causal pathway or a substantial public health impact, it does not diminish 
the importance of studying HEV in populations at high risk for complications – 
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Hepatitis E Background 
Hepatitis E is a viral infection with a dual nature: one present in developing countries, 
one present in developed countries. In developing countries, Hepatitis E is characterized 
by large waterborne outbreaks with significant morbidity and mortality – especially in 
pregnant women. In developed countries, waterborne transmission of Hepatitis E leading 
to clinical disease is negligible to non-existent; instead, it manifests sporadically without 
a clear source and with low morbidity 1. There are multiple and interrelated reasons for 
the manifestations to differ by country. Prime amongst them is the water supply in 
developed countries is more secure from pathogenic agents as compared to the water 
supply in developing countries. In addition to the difference in water supply, different 
genotypes of Hepatitis E are found in developed countries. In terms of public health 
impact, the predominant Hepatitis E genotype in the developing world is genotype 1, and 
the predominant type of Hepatitis E in the developed world is genotype 3. Genotype 2 
and genotype 4 also exist but appear to be less relevant than genotypes 1 and 3 in part 
due to their limited geographic scope. There has been a single verified case of genotype 
7 in humans 2. Hepatitis E is not unique to humans; it has been found to infect swine, 
bovine 3, deer, rabbit, mongoose, chicken, camel, rat, ferret, greater bandicoot, Asian 
musk shrew, mink, moose, and fish; some, but not all, of these animals host human-
transmissible Hepatitis E  4. Genotypes 3 and 4 have animal hosts, but genotypes 1 and 
2 are only found in humans. 
 
Hepatitis E Virus Characteristics  
The Hepatitis E virus is a single-stranded RNA virus of the Hepeviridae family and is 
genetically unrelated to the other hepatitis viruses. Like all viruses, the Hepatitis E virus 
consists of nucleic acids encapsulated in a protein structure called a capsid. Unlike 
some viruses such as Hepatitis D virus, Hepatitis E virus does not have a lipid envelope. 
Hepatitis E virus uses viral reproduction to replicate; viral reproduction is a process in 
which a virus gains access to the interior of a host cell, the viral genetic material is read 
by the host’s metabolic components, eventually resulting in creating copies of the virus. 
Its genome is 7.2 kilobases (kb) and contains 3 open reading frames (ORFs) – which are 
DNA or RNA segments that essentially define the proteins produced. Open reading 
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frame 1 (orf11) codes for a large, nonstructural protein with many functions; it is unclear if 
the proteins remains as a single protein or if it is cleaved into distinct functional units 
after translation 5. One of the units is suspected to be a methyltransferase that caps the 
viral RNA – a process that assists in the creation of protein and in the evasion of 
triggering a host immune response 6. A protease, a type of enzyme that cuts proteins, is 
also encoded by orf1; its role in Hepatitis E virus is unknown. A helicase is also encoded 
by orf1; helicases are essential to viral reproduction as they unwind genetic material 
allowing for its reproduction. This helicase is also thought to assist with the capping 
process done with the methyltransferase. orf1 also encodes for an RNA dependent RNA 
polymerase – an essential part of any RNA virus – this protein is responsible for creating 
copies of the genetic material. Open reading frame 2 (orf2) encodes the viral capsid. The 
viral capsid is not just a protective casing, but also has surface molecules that can serve 
a variety of roles – including to enter a host cell. The surface molecules can be proteins 
or other molecules (e.g. carbohydrates); they can be designed as part of the capsid its 
self, or molecules may attach to the capsid surface. The surface of Hepatitis E virus is 
populated by many protein-carbohydrate complexes known as glycoproteins. A study 
demonstrated even slightly altering capsid of Hepatitis E virus made it unable to infect a 
host 7. Characterizing the viral capsid is also important because vaccines train the 
immune system to recognize specific capsid elements and mark them for elimination. 
Because of the wide-ranging functionalities encoded by orf2, it has been the focus of 
much of the research on Hepatitis E genomics. Open reading frame 3 (orf3) encodes for 
a protein of unknown function which is predicted to be involved with extending the life of 
the cell, avoiding triggering an immune response and/or assisting in energy 
management 5. Because the immunological assays cannot distinguish between 
genotypes, examining the differences in the genome sequences is the only way to 
establish which genotype is responsible for an infection. 
 
Scope of Hepatitis E Genotypes 
Like other viruses, Hepatitis E has multiple strains. Outside of a single aberrant case, 
four different genotypes of Hepatitis E are found in humans: 1, 2, 3, and 4. These 
genotypes are not only genetically distinct, but also have different routes of transmission, 
                                                          
1 orf1 in italics and lower case references the gene; ORF1 capitalized and not italicized 
references the protein. For the purpose of the discussion, the terms are mostly interchangeable. 
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different endemic areas, and different at-risk populations. To understand the different 
presentation and different public health relevance between the developing world and the 
developed world, it is needed to understand the difference between the genotypes. 
Genotype 1: The virus now known as Hepatitis E was first implicated in a 1978 outbreak 
of hepatitis; in 1980, a paper hypothesized the 1978 outbreak was due to a heretofore 
undefined virus 8. In 1983, immune electron microscopy identified the structure of the 
virus responsible for Hepatitis E 9. In 1992, the genome of hepatitis E was sequenced 
from a case in Burma, identifying the genotype of what likely caused the first known 
outbreak of Hepatitis E 10. This genotype has been seen in some Asian countries, 
African countries, and South American countries. Genotype 1 has no known animal host 
other than humans. Genotype 1 is the strain responsible for most large outbreaks. Like 
the other genotypes of Hepatitis E, the transmission route is fecal-oral. It is most often 
spread through a contaminated water source, but also can be spread through vertical 
transmission 11. Proper sanitary habits, such as a reduction of defecation in fields can 
reduce the risk of an outbreak. It is not clear whether genotype 1 was previously present 
in developed countries then eliminated through securing the water supply or if genotype 
1 has never been endemic to developed countries. In addition, because of this strain, 
two vaccines against Hepatitis E have been developed – though the vaccines also 
protect against the other genotypes 12. 
Genotype 2: In 1992, a genetically distinct strain of Hepatitis E was identified in Mexico 
13. Apart from Mexico, this genotype has also been seen in some African countries. This 
genotype is generally mild, and few if any very severe cases have been reported 14. 
Genotype 2 has no known animal host other than humans. Like genotype 1, its primary 
transmission path is fecal-oral and is spread through contaminated water. Due to only a 
few geographic areas being affected and mild disease progression, genotype 2 is not 
regarded as a significant public health problem. 
Genotype 3: In 1997, a third genetically distinct strain of Hepatitis E was identified in the 
United States 15. The strain was noted for its high similarity to strains found in swine 16. 
This genotype has since been seen worldwide. Genotype 3 has been found in and 
potentially transmitted by swine, rabbits, mongoose 4, deer 17, and shellfish 18. While 
foodborne transmission is thought to be the primary mode of transmission, working with 
infected swine is a potential pathway 19 20. Genotype 3 may have distinct, granular 
geographic patterns. Genotype 3 has been found in wastewater 21, but it is not known 
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the extent to which transmission is waterborne. Unlike the other genotypes, type 3 has 
been implicated in chronic Hepatitis E, particularly in immunocompromised populations. 
Due to its widespread nature and ability to cause chronic Hepatitis E, genotype 3 likely 
ranks second of Hepatitis E viruses in terms of public health impact.  
Genotype 4: In 1999, a fourth genetically distinct strain of Hepatitis E was identified in 
China. This strain has been seen in other East Asian countries as well as a few 
countries in Europe. Genotype 4 has been found in and potentially transmitted by swine 
4. The potential for foodborne transmission leads to frequent comparisons to genotype 3. 
This genotype is not well understood; it has been suggested it may be more virulent than 
genotype 3 based on cell models 22 and epidemiologic data 23, but epidemiologic 
evidence supporting this notion may be the result of selection bias 24. Waterborne 
transmission of genotype 4 is suspected, but no cases have been definitively linked to 
waterborne transmission. Despite being potentially more virulent than genotype 3, its 
localized nature and lack of outbreaks suggests it overall public health impact is low. 
 
Symptoms and Detection 
Though transmission differs greatly between genotypes, clinical presentation in 
symptomatic infections is uniform between genotypes. When symptomatic, Hepatitis E 
has an incubation period of 15-60 days with a mean of 40 days and presents similarly to 
other hepatotropic viruses that induce hepatic inflammation 1. Symptoms may include 
fever, anorexia, arthromyalgia, pruritus, dark urine, diarrhea, nausea, headache, 
abdominal pain, asthenia, vomiting, purpuric rash and jaundice; these symptoms last for 
a month or more 25 26 27 28. During the course of a symptomatic infection, serum alanine 
transaminase (ALT) are sharply increased 29. Other biochemical changes occurring 
during a symptomatic infection include increased aspartate aminotransferase (AST), 
bilirubin, alkaline phosphatase, and γ-glutamyltransferase 30. Biochemical changes 
occurring in subclinical cases are not well understood. Risk factors for serious 
complications include pregnancy, immunocompromised status and cirrhosis 31. Serious 
complications include severe liver injury, acute liver failure, perinatal mortality for 
pregnant women, and death 29. The risk factors and complications vary by genotype; 
most notably, pregnant women have only been shown to be at greater risk when infected 
with genotype 1. Acute Hepatitis E has no specific treatment formally recommended 32, 
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but treatment with ribavirin has been highly effective in case studies and increasingly in 
the field as a whole 33 34 35.  
 
Due to the largely non-specific symptoms and similar presentation to other Hepatitis 
illnesses, suspected cases must be confirmed through diagnostic testing. While no FDA-
approved serological test exists, serological tests obtained from other countries are the 
most-used method of detecting Hepatitis E. In the recent past, in-house assays 
immunological assays were predominant, but now most assays are produced and 
marketed by companies to the institutions. There are several immunological assays 
currently available including, but not limited to Wantai, Euroimmun, MP, Dia.pro, DSI, 
Gene Labs, and Mikrogen; they all are based on detection of antibodies, not the virus 
itself. While there is some controversy regarding which diagnostic tests are superior 36, 
there are several similarities between all of them. The tests marketed now are argued to 
be superior than the in-house assays used previously 37. Despite Hepatitis E having four 
major genotypes, all major genotypes share a single serotype which makes 
immunological assays able to detect all major genotypes of Hepatitis E, but unable to 
distinguish between them. Immunological assays are effective in detecting both 
temporally distant infections – IgG is 89-100% effective in detecting cases within 2 years 
– and temporally proximal infections – IgM can detect 73% of patients within 26 days but 
~0% of patients 6-7 months after the infection is cleared 38. Despite the high sensitivity 
reported for IgG in general, some IgG tests are more sensitive than others. Notably, the 
sensitivity of the GL-type assay, which use a mixture of peptides from ORF-2 and ORF-
3, may be around 56% compared to the 98% sensitivity of the PE2-type assay, which 
uses structural peptides from ORF-2, despite both having similar specificities 39. The 
assay primarily used in the data available is the DSI DS-EIA-ANTI-HEV-G/M assay 40. 
This set of assays has high specificity in both IgM and IgG, 99% and 99% respectively, 
but substantially lower sensitivity, 63% and 72% respectively 41. A key drawback of 
immunologic assays is the reliance on a functional immune system; immunological 
assays are less reliable when used in patients who are immunocompromised – this is a 
critical gap because Hepatitis E can manifest as chronic Hepatitis E in 
immunocompromised individuals, and specific protocols can be used to treat chronic 
Hepatitis E 32. 
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PCR techniques show some promise in improving detection in ongoing or recent 
infections, especially in immunocompromised individuals 42. PCR techniques also have 
the advantage of being able to distinguish between different genotypes of Hepatitis E. 
Unfortunately, the quality of PCR techniques varies substantially from lab to lab 43. 
Another potential disadvantage of PCR is it detects viral RNA, so PCR cannot detect 
recent or distant cases where the viral RNA has already been cleared – more an issue 
for epidemiologic studies than for clinical purposes. A weakness of all techniques is 
diagnostic testing cannot identify cases if it is not performed. Two studies have shown a 
non-insignificant number – 22% and 3% –  of drug-induced liver injury cases in the 
developed world were actually due to Hepatitis E 44 45. Because testing for Hepatitis E is 
not consistently done in persons who may have it, incidence and prevalence estimated 
from clinical testing will underestimate the true incidence and prevalence of Hepatitis E. 
 
Hepatitis E in Developing Countries 
In many developing countries, Hepatitis E – genotype 1 in particular – is a major public 
health problem. However, Hepatitis E is not an endemic disease with a relatively stable 
incidence year-to-year such as malaria. Instead, Hepatitis E manifests in the form of 
sporadic and potentially large outbreaks – outbreaks that can exceed 100,000 cases 46. 
Large outbreaks such as these are almost exclusively caused by Hepatitis E genotype 1 
and mainly infects young males. These occurrences of Hepatitis E are only partially 
seasonal 47, and they are highly linked to the biogeography of the area 48. The mode of 
transmission is typically fecal contamination of the water supply 49, but some person-to-
person transmission has been reported – albeit it is still likely this was transmitted via the 
fecal-oral route 50. The attack rate of this Hepatitis E is fairly high – around 50% 51.  
 
The case-fatality rate of these Hepatitis E infections is not high – usually between 0.2% 
and 4%. Despite young men being more likely to be infected by genotype 1, pregnant 
women have exceptionally high morbidity and mortality – having a case fatality rate of 
10% to 25% 52. The reason for the much higher case fatality rate in pregnant women is 
not currently known. Due to large outbreaks and high mortality in vulnerable populations, 
two vaccines have been developed, but their impact is not currently known 12. In 
addition, transmission should be able to be interrupted by ensuring water meant for 
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human consumption has been boiled as the Hepatitis E virus cannot withstand 
temperatures over 70°C 53.  
 
The prevalence of individual genotypes in the developing world is not known because 
most of the testing is done through immunological testing – which cannot distinguish 
genotype due to the genotypes sharing a single serotype. There is some evidence that 
genotype 3 is rare compared to genotype 1 in places where genotype 1 is endemic. One 
piece of evidence is despite the widespread occurrence of Hepatitis E in developing 
countries, chronic Hepatitis E is extremely rare 54. As genotype 1 cannot manifest as 
chronic Hepatitis E, but genotype 3 does occasionally manifest as chronic Hepatitis E 
this supports the hypothesis that genotype 3 is rare compared to genotype 1 in places 
where genotype 1 is endemic. Nevertheless, it is possible that chronic Hepatitis E is not 
seen in the developing world for reasons other than low prevalence of genotype 3: 
reports of chronic Hepatitis E could be overshadowed by reports outbreaks of Hepatitis 
E and/or the at-risk population – namely transplant patients – is substantially smaller in 
developing countries versus developed countries.  
 
An important point is the above discussion of Hepatitis E in developing countries only 
applies to developing countries where genotype 1 (and to some extent genotype 2) is 
endemic. Many developing countries do not see Hepatitis E as a public health crisis due 
to the lack of genotype 1 – possibly either because they have a secure water supply or 
because of geographic considerations. In fact, the distinction between the developing 
countries and developed countries is severely undercut by a heterogeneity among the 
developing countries; for instance, Hepatitis E poses much less a public health problem 
to Latin American countries than Southeast Asian countries 55. The distinction between 
developing countries and developed countries is useful in that many large developing 
countries has endemic genotype 1; and few, if any, developed countries have endemic 
genotype 1 (table 1). 
 
Hepatitis E in Developed Countries 
In developed countries, Hepatitis E has been increasingly recognized as a potential 
public health concern since chronic Hepatitis E has been characterized. Apart from 
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chronic manifestations, Hepatitis E in the developed world is generally mild. The large 
outbreaks and the high fatality in pregnant women that are seen in developing countries 
are absent in developed countries. Rather than primarily affecting young men, Hepatitis 
E in developed countries primarily affects middle-aged and older men. Most infections 
are sporadic and asymptomatic. Due to this elusive nature, determining risk factors for 
infections has been difficult, and risk factors may vary between countries. The only mode 
of transmission implicated in outbreaks in the developed world thus far has been 
foodborne 56, but sporadic cases are far more common than outbreaks. Transmission 
causing sporadic cases may be foodborne, from close contact with infected animals – 
including hunting 57 –, from contaminated water, or from blood transfusions. People with 
jobs that bring them in contact with pigs 58, including pig farmers 59 60 and pig 
veterinarians 20 have been shown to be at substantially higher risk of infection than 
people with other occupations. Seasonality has been shown to have a minor impact in 
developed countries 61. Curiously, people infected with HBV were more likely to also 
have been infected with HEV 62. Cooking foods at temperatures above 70°C should 
prevent foodborne transmission 53.  
 
One common feature of Hepatitis E in developed countries is the potential for chronic 
Hepatitis E. Chronic manifestations of Hepatitis E is a relatively newly discovered facet 
of the infections – it was not described in the literature until 2008 63. There is no formal 
definition of chronic Hepatitis E, but it is generally regarded as an infection lasting at 
least 3-6 months 64. In cases of chronic hepatitis E, a smaller proportion of the cases are 
asymptomatic and cirrhosis of the liver is more common – leading to higher mortality 
rates 65. Other serious complications – such as Guillain–Barre syndrome 66 and impaired 
kidney function 67 – may be caused by chronic hepatitis E, but further research is 
required. Chronic hepatitis E is most likely to occur within someone 
immunocompromised, including HIV infected individuals, individuals with hematological 
cancers, and most frequently seen in individuals with solid organ transplants. One study 
showed approximately 66% of solid organ transplant patients infected by Hepatitis E 
virus developed chronic Hepatitis E 65. The dominant pathway for infection in these 
cases is not known. Blood transfusions may be a likely source in transplant cases 68, but 
more traditional pathways are more likely in patients who are immunocompromised for 
reasons other than solid organ transplants or not immunocompromised at all. The 
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treatment of chronic hepatitis E may differ from strictly supportive care which is 
traditionally used in acute Hepatitis E – either ribavirin, pegylated interferon-α, or a 
combination of the two are valid treatments. Pegylated interferon-α is often discouraged 
due to potentially serious side effects. In extreme cases, a liver transplant may be 
performed 32. 
 
Like the heterogenous nature of Hepatitis E in developing countries, there appear to be 
substantial differences of Hepatitis E prevalence and overall impact in developed 
countries as well. The difference of prevalence in developed countries is not understood 
and may be due to factors from geography to culinary practices – especially in terms of 
pork consumption. For instance, most of the chronic Hepatitis E cases come from 
Europe and few appear elsewhere – such as the United States. The reason for this is 
unknown but may tie into differences in overall prevalence and patterns of infection. 
Because chronic Hepatitis E is a serious condition, Hepatitis E in Europe has been the 
subject of significantly more scholarship than Hepatitis E in the United States. Examining 
Hepatitis E in the United States may lead to a greater understanding of why Hepatitis E 
appears to be a more significant health concern in Europe than in other developed 
countries. 
 
Though several studies have examined Hepatitis E in the United States, neither the 
prevalence nor the impact of Hepatitis E is well-understood. Previous studies have found 
unacceptably large ranges of possible seroprevalence and lacked either statistical power 
or directness in their data and research question. The aim of this project was to further 
characterize the prevalence of Hepatitis E, review the risk factors, examine at-risk 
populations, assess liver function and estimate the potential impact. The primary aim, 
specifically, was to assess the seroprevalence across the United States.  
 
The two secondary aims of this study were: (i) investigate the vastly differing findings 
between continuous National Health and Nutrition Examination Survey (NHANES) and 
NHANES III using new serological testing data, (ii) examine biochemical changes in liver 
function in people with recent infection to better understand the mechanism for liver 
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damage in Hepatitis E infection and why some populations are at greater risk. This 
project utilizing data collected by NHANES between 2009-2016. Sera collected from 
NHANES III, but tested as late as 2013, will also be used. 
 
The NHANES Study 
The NHANES study is conducted by the National Center for Health Statistics, a branch 
of the CDC 69. The NHANES study has been active since the 1960’s. Its goal is to 
comprehensively assess the nutrition and health of adults and children in the United 
States. NHANES combines both surveys and physical examinations. One of the 
NHANES priorities is to create a nationally representative sample, so it provides weights 
to simulate the U.S. population based on their samples. In this way, the NHANES study 
sets the national standards for weight, height, and blood pressure. In addition, most of 
the data collected is released to the public for further data analysis by independent 
researchers. NHANES has numerous studies based on its data, with a wide range of 
study topics including diverse fields such as: cardiovascular disease, mental health, 
medication use, nutrition.  This paper will primarily use serological testing for Hepatitis E, 
which was conducted in years 1988-1994 and 2009-present. 
 
Dissertation Objectives 
My dissertation includes three manuscripts. The first manuscript covers the primary aim 
of characterizing demographic characteristics, risk factors, and short-term trends in 
Hepatitis E. The second manuscript examines the various serological assays used on 
the NHANES III samples. The third manuscript examines the liver function sub-study. 
These three manuscripts are a much-needed updated to our current knowledge of 
Hepatitis E in the United States as well as contribute to a greater understanding of 







This study will use the data provided by NHANES. The study will only examine data from 
years that included Hepatitis E serological testing. Most data will be from the continuous 
NHANES (years 2009-2016), but some data will be used from NHANES III (1988-1994). 
Prior to 1999, NHANES were numbered (I, II, and III) collected data over a span of 
several years, then waited several years until beginning the next set of data collection. In 
1999, NHANES began continuously collecting data. Both the continuous NHANES and 
NHANES III are cross-sectional studies that have been used to calculate national 
statistics.  While it is possible to calculate nationally representative statistics based on 
NHANES, the raw sample is not nationally representative – it oversamples minority 
groups to provide more accurate subgroup statistics. The methodology of sampling 
within the NHANES study is not consistent between studies as sampling methods and 
important sub-groups continue to change. Despite the changing methodology behind 
NHANES, the weights are similarly adjusted to ensure that different cycles of NHANES 
can be directly compared to one another 70. In addition, NHANES only covers non-
institutionalized civilian residents of the United States which includes resident non-
citizens but excludes active duty military personnel and U.S. citizens living overseas. 
 
NHANES Sampling Methodology 
NHANES uses a 4-stage multi-cluster design: counties, segments, households and 
individuals. The goal of NHANES is to create a self-weighting sample within each 
demographic group of interest – that is, within each of the 87 demographic subgroups, 
every individual has the same chance of being selected –, to create a nationally-
representative sample, and to be cost-effective and efficient; this three-pronged goal 
necessitates a complex methodology in each of its four stages. The complexity is 
highest in the first stage and in the fourth stage. In short, the county stage favors 
counties with large numbers of oversampled groups (i.e. groups that are sampled more 
than they would be in a simple random sample) and counties that have not been 
selected before; the segment stage favors census tracts with large numbers of 
oversampled groups; the household stage is a simple probability sample; the individual 
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level favors people from oversampled demographics and maximizes number of people 
sampled per household. 
 
The primary sampling unit (PSU) consisted of counties – or county-equivalent regions – 
individually or in sets of adjacent land if there were too few people living within the 
originally selected county. Most of the PSUs were individual counties; from the ~3,100 
counties in the U.S., 2,846 PSUs were formed. These PSUs were then selected at 
random through probability-proportion-to-size sampling. The Measure of Size (MOS) 
used to establish the size for weighting was derived from the U.S. 2000 Census and 
updated to account for large growth since that census. The MOS is not simply a raw 
population count, but a weighted average of estimated populations by race and Hispanic 
origin. This sampling methodology is done to ensure a mix of low-population and high-
population counties exist in the NHANES county sample and that counties/groups with 
substantial number of populations selected for oversampling are more likely to be 
selected. Various other methodologies were applied to the PSU selection algorithm, 
such as the Ohlsson’s method to minimize the chance a county selected in one year’s 
sample had not been selected in a previous year’s sample. The initial goal for number of 
people sampled in each PSU is 333, but is the goal was then re-adjusted per PSU to 
sample more people in PSUs that contain more people overall – especially more people 
representing demographics that will be oversampled.  
The second stage consisted of a similar probability-proportion-to-size sampling as the 
county-level including a similar MOS algorithm, but instead it being used to select 
census blocks within the counties. While the general structure of the sampling 
methodology is similar between the first and second stage, the second stage has fewer 
added complexities – for example, it does not use the Ohlsson’s method. 
The third stage consisted of dwelling units (DU) or households. Within the selected 
census blocks, all DU were listed and of those, a subsample was selected. DU were 
selected with approximately equal probability; the necessary weighted sampling to 
obtain a nationally representative sample of households was conducted in the previous 
two stages and oversample demographic groups of interest was conducted in the first, 
second, and fourth stage. There were approximately equal numbers of households 
sampled in each segment selected. 
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Each sampled DU was then screened to determine if it was occupied, vacant, or if it 
were only occupied at certain times; only full-time occupied DU were retained in a list. 
From the list, a subsample of persons from each household were selected based on a 
combination of sex, age, race, Hispanic origin, and income – elements that constitute the 
87 demographic subgroups of interest. The methodology also maximized the number of 
people per household sampled to increase the efficiency by minimizing the number of 
households required to achieve sufficient numbers of each of the demographic 
subgroups 70.  
 
The expected breakdown of each year’s data collection of NHANES is 15 PSUs will be 
selected. From that, 360 segments will be selected and 11,500 households within the 
segments will be screened. From those households, an expected 6,888 persons will be 
sampled, and 5,000 persons ultimately examined (figure 1). Because each NHANES 
cycle is two years, the estimated number of people examined in each cycle is 10,000. 
 
This type of design is a departure from relying on random selection for representative 
selection; because random selection is an assumption made in many statistical 
procedures, special care needs to be taken in deciding how the data will be analyzed. 
While it is obviously essential to use survey weights to account for the design for 
calculating statistics relevant to the population simulated by the study (e.g. prevalence, 
averages), it is also important to account for survey design in regression models 
designed to report measures of disease association (e.g. relative risk). Even a well-
adjusted regression model with sampling parameters included in the model as potential 
confounders can result in erroneous standard deviations if not accounting for the survey 
weights.71. Nevertheless, many studies use inadequate techniques for this type of 
complex survey design – some estimates are as high as 40% do not account for the 
sampling methodology 72. Fortunately, each of the three major statistical analysis 
software has at least one method of accounting for complex survey design: R has 




NHANES Data Collection 
In the continuous NHANES, each year, mobile health centers are deployed to 15 
different counties across the United States collecting data on approximately 5,000 
people in total. The small number of counties collected per year means it cannot be used 
to make inferences on granular regions across the nation, but it can be used to establish 
more general regional differences (e.g. upper Midwest vs New England). The individuals 
are sampled initially for a house-hold screener which determines if any household 
members are eligible for the NHANES study. Eligible and consented individuals are then 
examined through combination of physical examinations, laboratory testing and 
household surveys. While the physical examinations and sample collection are 
performed within the mobile health centers, the health interviews are done in the 
participants’ homes. The study team for each of these mobile health centers consists of 
a physician, medical and health technicians, and dietary and health interviewers. The 
survey data collected is directly entered in electronic form to decrease the likelihood of 
paperwork errors.   After the data is collected and processed – including removal of 
personal identifiers – the data is made public to accommodate researchers. A subset of 
the data is withheld because it contains potentially identifiable information and/or highly 
private information; this withheld data can be accessed through an application process 
through the National Center for Health Statistics (NCHS) to access the data in specific 
locations to ensure the data cannot be used to identify persons or disseminated. 
Because of the wide nature of the term ‘health’ and variable funding, the data collected 
by NHANES has changed over time. Data has been collected through 2016, but it takes 
a substantial amount of time for collected data to be cleaned, de-identified and released.  
 
The survey collected by NHANES includes demographic information, sexual behavior, 
drug use, two 24-hour food recalls and related dietary questions, cognitive and 
behavioral information, health conditions, etc. Though two 24-hour recalls were done, 
and Hepatitis E in the U.S. is thought to be most commonly foodborne, two 24-hour 
recalls are not enough for risk analysis. The only data potentially relevant to Hepatitis E 
that could be used was in the auxiliary questionnaire accompanying the 24-hour food 
recall – it includes shellfish consumption over the last 30 days and water source. The 
2009-2010 cycle contained additional nutrition information section, but that has already 
been published in a previous study. The other data from the questionnaire used in this 
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study is primarily demographic – to characterize patterns of Hepatitis E – and health 
conditions – to examine individuals potentially at greater risk for infection or serious 
outcomes. 
 
The physical and laboratory examination data includes blood pressure, body 
measurements, X-rays, oral examinations, serological testing, nutrient assays, urine 
tests, and a standard biochemistry panel. The exams include a multitude of chemicals 
and enzymes that are related to liver function: alanine aminotransferase (ALT), alkaline 
phosphatase, aspartate aminotransferase (AST), total bilirubin, and platelets. Other data 
that will be included in the physical and laboratory examination data includes serological 
tests of Hepatitis E and other Hepatitis viruses – to examine for comorbidities. 
 
Lab Testing of Hepatitis E 
As of 2009, NHANES began serological testing of participants for Hepatitis E for the first 
time since it began continuously collecting data. Prior to this, the last time NHANES 
conducted serological testing for Hepatitis E was in NHANES III (1988-1994). As 
Hepatitis E is not a reportable disease and not routinely tested for even in the presence 
of liver ailments, it is difficult to assess the prevalence and impact of Hepatitis E outside 
of a study such as NHANES. Even NHANES cannot completely discern the prevalence 
and impact because Hepatitis E is often acute rather than chronic and neither the 
pathogenicity nor the virulence is well-defined in United States or other similar 
developed countries. 
 
The NHANES III sera was analyzed with an in-house immunoassay, the DS-EIA-ANTI-
HEV-G/M assay, and the WANTAI IgG and Western blot. Each of these assays are 
characterized as positive or negative; there is no indeterminant categorization. The 
recent NHANES cycles perform two types of serologic testing for Hepatitis E: DSI DS-
EIA-ANTI-HEV-M – an IgM assay – and DSI DS-EIA-ANTI-HEV-G – an IgG assay. Both 
assays are produced by Diagnostics System (Soronno, Italy) (table 2). The IgG test has 
been verified to have a sensitivity of ~97.5% and a specificity of ~100% 73, but the IgM 
has not been as thoroughly characterized. While both are immunological assays, and 
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both can detect all genotypes of Hepatitis E, IgM detects if there has been a recent 
Hepatitis E infection, and IgG detects if one has ever had a Hepatitis E infection. While 
IgM theoretically provides a reasonable basis for the current prevalence of Hepatitis E, 
IgG cannot be the basis for current prevalence but can serve as an estimator for overall 
population-level risk. Using recent Hepatitis E infection is superior for finding proximal 
risk factors, but far fewer people were recently infected than ever being infected, 
diminishing the advantage of using the IgM. In contrast, IgG cannot identify proximal risk 
factors, but would be able to identify lifestyle risk factors assuming the relevant lifestyle 
risk factors did not change between the time of infection and the time of data collection. 
Due to the low numbers of people with an ongoing or recent infection of Hepatitis E, this 
study will use IgG when practical. 
 
Data Set 
Public use data from the Continuous NHANES, years 2009-2016 – four cycles – were 
included in the analysis. Variables were taken from HEV serology, dietary data total day 
1, demographic, medical conditions, alcohol use, drug use, standard biochemistry 
profiles, and other hepatitis serology. The data was combined and cleaned using R 
3.3.2.  
 
For the Continuous NHANES years 2009-2016, we used parts of the restricted data set. 
This subset of data is withheld from public release due to its sensitive nature. Data 
considered to be sensitive includes personally-identifiable information – such as the 
location of their home – and information on vulnerable persons, such as information 
regarding one’s pregnancies or information on youth – such as sexual behavior and drug 
use. To ensure the privacy of the participants, this data can only be accessed at certain 
sites. Any analysis must be done in the presence of a federal employee with appropriate 
clearances. These sites do not permit data to be taken in or taken out without review of 
an analyst. The access site we will use is the census restricted data center (RDC) site 
on UMN campus. While public documentation on the variables within the RDC is 
incomplete, both geographic and occupational data are included in the restricted dataset 
and will be used in the study. The data is combined and released to the researcher by a 




Only public use NHANES III, years 1988-1994, data was utilized. The primary NHANES 
III dataset was compiled in SAS and exported into R. Supplementary datasets examining 
Hepatitis E serology were appended to the primary dataset in R 3.3.2 where it was later 









Previous estimates of HEV IgG seroprevalence in the United States sourced from the 
NHANES dataset ranged from 21% in 1988-1994 to 6% in 2009-2010. Since 2010, 
seroprevalence has not been reported. We evaluated the seroprevalence trend after 
2010 and demographic patterns and tested for potential risk factors. 
This study uses data collected from NHANES 2009-2016, specifically HEV IgG and IgM 
serology of non-institutionalized U.S. residents 6 years old and older. The weighted 
seroprevalence calculation for the U.S. population and demographic segments as well 
as age and sex-adjusted risk factor analysis were performed. 
HEV IgG seroprevalence across 2009-2016 was 6.1% (95% CI: 5.6%, 7.0%) with 
approximately 1% of samples testing positive also for HEV IgM. HEV seropositivity was 
associated with race – especially high in non-Hispanic Asians (12.8%; 95% CI: 11.1%, 
14.7%) – and being born outside of the United States (9.4%; 95% CI: 8.1%, 10.7%).  
This study found the HEV seroprevalence in the United States to be largely stable over 
2-year increments from 2009 through 2016. Additionally, we observed that non-Hispanic 
Asians were more likely to be HEV seropositive when compared to other races. Non-
Hispanic Asians at higher risk should be accounted for in future Hepatitis E cohort or 
cross-sectional serological studies. 





Hepatitis E is an infection caused by the Hepatitis E virus (HEV) often presenting acutely 
as an asymptomatic or a non-specific febrile illness, but it also has potential for fulminant 
liver damage or chronic infection leading to liver-related complications and death, 
especially in immunocompromised people 25 26 27 28. There have been few studies 
examining prevalence of HEV in the United States because the virus was recently 
discovered in the U.S. in 1997 and has not been perceived as an urgent health crisis. 
Interest in evaluating the threat posed by Hepatitis E in the United States has increased 
since 2007, when chronic manifestations were first noted in immunocompromised 
individuals 74. 
Two estimates of HEV seroprevalence from U.S. national studies document that HEV 
infection is not uncommon in the general population: 21% 75 and 6% 76. These studies 
were published based on serologic tests collected by the National Health and Nutrition 
Examination Survey (NHANES) in years 1988-1994 and 2009-2010. The 1988-1994 
seroprevalence study is of note because it offers a perspective of Hepatitis E during a 
time when it was not known to be endemic in the United States. Also, there appears to 
be a decline in the seroprevalence over the 15 years with no concerted interventions 
directed at the disease.  If HEV infections are truly decreasing without intervention, 
reasons for the decline should be investigated. Has the seroprevalence truly declined 
sharply over the course of 15 years or are other external factors driving this change?  
One possible explanation could be the conflicting results from in serological tests used to 
evaluate HEV over the course of the last 15 years.  In addition, it is important to better 
understand risk factors that may change over time that could impact Hepatitis E in the 
United States.  
The risk factors and demographic patterns of HEV serostatus in the United States are 
poorly understood. Of two major studies examining HEV serostatus in the U.S., one 
study used NHANES sera from 1988-1994 77, and the other study had examined 
demographic patterns using the 2009-2010 cycle but was not able to find many 
significant patterns 76. Having three times as much timely data from new NHANES 
waves allows for examination of sub-groups with more precision; with the additional data 
collected since the 2009-2010 cycle, we can more precisely detect differences in 
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demographic and potential risk groups. As such, this analysis will pool the available 
cycles together to determine an average prevalence for the specific demographic group. 
In the U.S. age has been the only demographic characteristic consistently associated 
with HEV infections. The HEV-age association has been extensively corroborated in 
studies conducted in other countries  – while in part due to HEV seroprevalence tests 
detecting any infection in one’s life, there has been indication that symptomatic HEV 
infections are more common in elderly populations 27 25.  Other demographic 
characteristics including race/ethnicity, being born in the U.S., military service, 
education, and poverty has had conflicting or insufficient evidence 76 75 77 73 and data 
from other countries has limited applicability. 
Risk factors linked to specific transmission path such as waterborne, foodborne, and 
bloodborne, have not been established in the U.S. While waterborne infections are not 
typically thought of occurring in developed countries and has not been implicated as a 
risk factor in the U.S. 75 76, HEV has been found in water in countries such as 
Switzerland and Canada 21 78. Similarly, shellfish consumption has not been specifically 
implicated as a risk factor in the U.S., but has been linked to infections in other 
developed countries 56 79 80. Finally, while bloodborne transmission of HEV has not been 
clearly established as a major pathway 81, transmission of HEV through blood 
transfusion represents potential public health threat because chronic Hepatitis E can 
manifest in immunocompromised populations who receive blood transfusions 65. Some 
countries, but not U.S., have begun to screen blood donors for HEV for this reason 82. 
Each cycle of NHANES contains approximately 9000 participants sampled from 30 
counties in the U.S. In each cycle, approximately 450 participants have been infected by 
Hepatitis E as shown by IgG test, and approximately 50 participants test IgM positive for 
recent infection. Thus, taken alone, each cycle can provide a reasonable estimate of 
HEV IgG seroprevalence, but the estimates for IgM seroprevalence would not be stable. 
The goal of the study is to use the updated NHANES datasets to re-examine the 
prevalence, short-term trends, and lifetime risk factors of HEV in the U.S. population. A 
more detailed characterization of HEV in the United States may lead to increased 
awareness and testing in at-risk populations – such as those immunocompromised 
whose past infections may re-activate 1 – and those exhibiting Hepatitis E symptoms. A 
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downward trend over the 6-8 years covered could also indicate that the HEV prevalence 




The data analyzed is from years 2009-2016 of NHANES. NHANES is conducted by the 
National Center for Health Statistics branch of the U.S. Center for Disease Control and 
Prevention. The source population is the entire United States, but the sample collected 
is clustered at multiple stages and stratified. The resultant sample contains weights to 
simulate the U.S. population. Thus, the results presented are representative of the entire 
non-institutionalized, civilian, resident U.S. population 69.  
Variables 
NHANES contains variables collected both via questionnaire and via laboratory sample 
testing. The majority of the variables assessed in this study are collected via 
questionnaire with the exception being the serological assay results for HEV infections. 
The variables analyzed by the study fall into two categories: 1) demographic variables 
characterizing variations in HEV seroprevalence across groups and 2) potential 
transmission pathways – blood transfusions, shellfish consumption, and tap water 
source.  
Age was examined in strata of 10 year increments up to age 80 and above 80. Gender 
was characterized as male or female. Race/ethnicity was characterized once as Mexican 
American, other Hispanic, Non-Hispanic white, Non-Hispanic black and ‘other race’ 
(including multiracial) except when looking at 2011-2016 data that included non-Hispanic 
Asian as a distinct category. Birthplace was characterized as born in the U.S. (both 
states and territories) or born outside of the U.S. Additionally, immigrants were analyzed 
for years lived in the United States categorically as years =<5, 5 < years =<10, 
10<years<=20, 20<years<=30, and years>30. Education was looked at as less than high 
school education, or high school education and greater. Poverty level was analyzed as 
below the poverty line, or at or above poverty line. Military personnel included anyone 
who had been a member of the Armed Forces of the U.S. including U.S. Army, Navy, Air 
Force, Marine Corps, Coast Guard, and members of the Reserves and National Guard 
whose units were activated.  
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Water source was analyzed as community supply, well or rain cistern, spring, don’t drink 
tap water, and other. Shellfish consumption was characterized as shellfish eaten in the 
last 30 days, yes/no; we assumed if someone consumes shellfish in the last 30 days, 
they eat shellfish with some regularly. Blood transfusions were analyzed as ever having 
a blood transfusion or never having a blood transfusion. 
The outcome variable used was seropositive as ascertained by the DSI DS-EIA-ANTI-
HEV-G/M (DSI, Italy) assay. This assay is the only assay used to determine HEV 
serostatus in the continuous NHANES study. The findings reported are IgG, which is 
positive if someone has been infected. Results from the assay are characterized as 




The average seroprevalence over all data available for years 2009-2016 and for 
individual cycles covering, 2009-2010, 2011-2012, 2013-2014, and 2015-2016 
separately.  
All data analysis was done using R 3.3.2 with Hmisc, dplyr, lme4 and survey libraries. 
Participants without HEV serology data were removed from data analysis. The primary 
outcome variable for seroprevalence was IgG positivity. NHANES uses a complex 
survey design that has clustering on multiple clusters, employs stratification, and 
oversamples certain demographic groups. These methods are essential for conducting 
the survey efficiently through narrowing the geographic scope from the entire U.S. to a 
small proportion of the counties, but they are a deviation from a simple random sample – 
the basis of many commonly used statistical techniques. Because NHANES does not 
use simple random sampling, specialized functions are required to obtain unbiased 
estimates and accurate standard error.  
In R, the survey library contains functions to process survey design data and to properly 
analyze the survey design data post-processing. The svydesign function from the survey 
library was utilized to process the survey design data via applying weights and 
accounting for stratification and clustering. NHANES provided variables for clusters 
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(sdmvpsu), strata (sdmvstra) and weights (wtmec2yr)2. Once the survey weights, strata, 
and clusters were all accounted for by using the svydesign function, seroprevalence was 
calculated. 
Prevalence estimates were done using the svyciprop function with the output of the 
svydesign function as one of the parameters. 
 
Demographic Analysis 
Like the prevalence analysis above, this was a descriptive analysis. HEV IgG 
seropositivity was used as the outcome variable and results was reported as the 
estimated percent of population seropositive with a 95% confidence interval. Identifying 
statistically significant differences was not the goal of the analysis; instead, it was to 
characterize the burden of HEV in subpopulations. 
To accomplish this, the svydesign function and the svyciprop function were combined 
with a specialized subsetting function from the survey package, subset.survey.design. 
This permitted examination of seroprevalence in individual demographic groups. 
Performing the subsetting within the svyciprop was required because native R subsetting 
may delete important structural information, such as clusters or stratas, that are required 
to accurately estimate the standard deviation. A multivariate analysis containing these 
variables was conducted in the risk factor analysis, no multivariable model was run. 
Because NHANES creates a representative sample based on gender/age/race 
characteristics, those variables can have accurate measures of seroprevalence 
calculated. Birthplace, education, and poverty index were not a part of the sampling 
algorithm NHANES so seroprevalence estimates and standard error may be distorted.  
 
In addition to the prevalence estimates, risk ratios were obtained for most if the 
covariates in the study via the svyglm function with a quasibinomial family and log link. 
The primary outcome variable for seroprevalence was IgG positivity. Age and gender 
were included in all models as potential confounders.   
                                                          
2 wtmec2yr can only be applied for analysis of a single 2-year cycle of NHANES. These weights 
were converted to 8-year weights (wtmec8yr) by dividing each cycle’s weights by 4 for analysis of 
the full 4 cycles.  
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An additional multivariate analysis tested the interaction between birthplace and 
race/ethnicity. This analysis was done because there is an unequal distribution of HEV 
across the globe, and some racial groups outside of the U.S. may come from regions 
with greater burden than others. 
  
Transmission Pathway Analysis- 
Svyglm was used with a quasibinomial family and log link to conduct a multivariable 
logistic regression for risk factor analysis. First, each transmission pathway variable – 
blood transfusions, water, and shellfish – was tested independently in a model with age 
and gender. Then a multivariate model was conducted to account for potential 
confounding and better assess the potential transmission pathway variables. This 
multivariate model contained race/ethnicity and being born in the US as additional 
potential confounders.  
 
Results 
Seroprevalence in U.S. Population 
The estimated national seroprevalence of HEV IgG averaged across 2009-2016 was 
6.1% (95% CI: 5.6%, 7.0%). In 2009-2010, the seroprevalence was 5.96% (5.1%, 7.0%). 
In 2011-2012 the seroprevalence was 5.82% (4.6%, 7.0%). In 2013-2014 the 
seroprevalence was 4.6% (3.7%, 6.0%). In 2015-2016 the seroprevalence was 8.08% 
(7.0%, 10%). The seroprevalence for the short-term IgM assay varied between 0.5-1.5% 
each year with 2009-2015 overall estimate to be 1.02% (0.8%, 1.2%). Table 3 contains 
detailed HEV IgG and IgM results for each of the years and the overall estimate and 
indicates no short-term trend in seroprevalence exists. 
 
Demographic Patterns of Seroprevalence 
Table 4 shows a detailed breakdown of HEV IgG seroprevalence by demographic 
characteristics such as age, sex, race, birthplace, education level, and income. As 
expected, the IgG (lifetime seroprevalence) increases with age. Females had slightly 
higher seroprevalence than males. With respect to race, non-Hispanic Asians had 
significantly higher seroprevalence than any other ethnicity (12.8%) followed by non-
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Hispanic whites (6.8%) the other racial groups – non-Hispanic black, Mexican-American, 
other Hispanic, and other all had between 2% and 5% seroprevalence. Those born 
outside the U.S. had a higher seroprevalence than those born inside the U.S. (9.4% to 
5.5%). Little difference in seroprevalence was found different education groups and 
different income groups. 
Table 5 shows the association between demographic variables and HEV IgG presented 
as risk ratios. Age and gender were not included because they were treated in each of 
the models as potential confounders. The only different conclusions from the 
seroprevalence table was military status was shown to provide a statistically significant 
protective effect (RR 0.69; 95% CI: 0.53,0.90) and years spent in US seem to be less 
significant. 
Table 6 shows the interaction between racial/ethnic background and birthplace. 
Consistent with the simpler models, most racial/ethnic groups were at higher risk if born 
outside of the US. Notably, Mexican-Americans born in the US were less likely to have 
been infected with HEV compared to Non-Hispanic Whites born in the US (RR 0.36; 
95% CI: 0.23,0.55); but Mexican-Americans born outside of the US were more likely to 
have been infected with HEV (RR 1.86; 95% CI: 1.45,2.37). Also notable is while the 
simpler analysis found Non-Hispanic Asians to be at higher risk than Non-Hispanic 
Whites, this model shows only foreign-born Non-Hispanic Asians were at greater risk. 
 
Transmission Pathway Analysis  
In addition to the demographic variables being expressed in table 5, the transmission 
pathway variables also are present. These analyses found non-significant results with 
respect all the transmission pathway variables: blood transfusion, shellfish consumption, 
and tap water source. 
In the final multivariate model (table 7), the transmission pathway variables remained 
statistically insignificant. Being born outside of the U.S., race/ethnicity (Asians combined 
with other group in order to include years 2009-2010), and age were the only statistically 





Seroprevalence and Demographic Estimates 
The observed seroprevalence estimates was 6.1% and was similar to those found in the 
previous paper analyzing the continuous NHANES HEV serology – 6.0% 76. The 
individual 2-year seroprevalence cycles are also similar, with highest seroprevalence in 
2015-2016 and lowest seroprevalence in 2013-2014, 8.08% and 4.6% respectively. The 
highest seroprevalence occurring in the most recent cycle casts doubt on any continuing 
downward trend of HEV seroprevalence. The low IgM seroprevalence is suggestive that 
there did appear to be a significant upwards trend in HEV seroprevalence associated 
with age. This trend appeared steady and is consistent with other findings that infections 
occur at all ages 51. It is unclear if the transmission pathways or genotype acquired 
differs in persons who are infected by HEV at different ages; a laboratory-based 
surveillance study found persons who acquired HEV abroad were much younger on 
average than persons who acquired HEV domestically 73.   
 
We observed that non-Hispanic Asians had a significantly higher average 
seroprevalence (12.8% vs national average of 6.1%). Prior to 2011, non-Hispanic Asians 
were not included as a demographic group of interest. The reason for this observation is 
unclear but it remains significant after taking into consideration demographic variables of 
age and gender. Asians born outside of the U.S. seem to be driving the trend of higher 
seroprevalence for their racial group. However, certain racial groups appear to be less 
likely to have been infected by HEV than others. This is especially the case of Mexican 
Americans. This association is clearly not due to immigration from a low HEV-burden 
country as the foreign-born Mexican Americans were more likely to have been infected. 
In general, people born outside of the U.S. have higher seroprevalence, suggesting 
foreign acquired cases of HEV is a significant contributor to the overall national 
seroprevalence in the U.S. 
Two additional demographic findings were unexpected; military status and immigrants 
having spent 5-10 year in the U.S. both were statistically significant in the models 
adjusting for age and gender. A risk association between HEV and military personnel 
would have been unsurprising if found to be a positive association, as this population 
can travel abroad for prolonged periods of time (i.e. deployed to developing countries). 
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However, the observed association was inverse. The higher prevalence in persons born 
outside of the U.S. who spent 5-10 years in the United States compared to those 
spending over 30 years was no longer statistically significant when including race in the 
model. This association could be explained by either type 1 error or variability in the 
country of origin of immigrants during different periods of time leading to a differential 
prevalence of HEV.  
 
Transmission Pathway Analysis 
In both the univariate and the multivariate analysis, the potential transmission pathway 
variables were not found to be associated with previous HEV infection. These findings 
are consistent with other studies in the US. While this study did not find evidence of an 
association between HEV, unsafe water, shellfish, and blood-born transmission, it does 
not exclude them as potential risk factors. Like the previous population-based analyses 
of HEV in the U.S., this study has the weaknesses of temporality and transient 
exposures (e.g. one may have a blood transfusion after having been infected by HEV, or 
one could have been infected by HEV while living in a place with an unsafe water source 
but has since moved). Notably history of blood transfusion does not have issues of being 
transient but was still null, suggesting that HEV is truly not often transmitted via blood in 
the United States. 
Study Limitations 
Though the additional data from years 2011-2016 improved our ability to detect smaller 
associations and temporal trends, the NHANES dataset did not substantially change, so 
structural limitations of NHANES still exist. One key limitation of the NHANES dataset is 
while they include two 24-hour food recalls, but for in-depth risk factor analysis, more 24-
hour recalls are required. This precludes using NHANES to investigate the highly 
suspected pathway of pork consumption. In addition, HEV has a prolonged incubation 
period likely make 24-hour food recalls relevant. 
The NHANES dataset, for reasons such as ease of data collection and preventing 
identifiability occasionally presents variables in categorical formats when a continuous 
variable may be more illuminating – for example, if time in U.S. were categorized 
continuously, we may be better able determine if the 5-10 year cohort is indeed at higher 
risk. Other categorizations were not as granular as needed; for example, non-Hispanic 
28 
 
Asians were not a racial categorization in all cycles, and birthplace being designated as 
“not in the U.S.” is overly vague.  
In addition, NHANES chooses a limited number of geographic regions per cycle, leading 
to a potential increased variability between cycles – which could be the source of the 
2015-2016 cycle having higher seroprevalence than previous cycles. There may be 
other potential confounders that have not been collected as well. Finally, NHANES is a 
cross-sectional study; while many of the demographic variables are constant (e.g. race, 
birthplace), other variables (e.g. tap water source) may change over time. Thus, the 
ability to detect associations between some of the variables and HEV infection are 
hampered due to problems of temporality. 
 
Future Directions 
Continued research using HEV IgG and IgM seroprevalence is possible. The clearest 
future direction is a continuation of tracking national seroprevalence through NHANES 
for as long as NHANES includes the measures. This will allow for further examinations 
of temporal trends and potentially incorporate new variables introduced to NHANES.  
Another potential direction would to design a cross-sectional study examining the 
potential link between pork consumption and HEV infection. Due to low seroprevalence 
in the general population and changing dietary patterns, it may be difficult to find an ideal 
population. Restricting to young-to-middle-aged adults would increase the prevalence in 
the sample. Further demographic studies, especially geographic analyses may further 
identify the optimal population to examine potential associations between pork 
consumption and HEV infection.   
One potential problem of using a cross-sectional study to examine a relationship 
between HEV infection and pork consumption is immigrants from and travelers to highly 
endemic areas. The contribution of immigrants and travelers to average national 
seroprevalence is not known, though some effort has been made to characterize how 
many HEV infections were acquired abroad 73. Further studies could examine the HEV 





This study examined HEV seroprevalence in the United States in years 2009-2016. We 
found that seroprevalence has not changed significantly in this time period and remains 
near 6%. Increasing age was consistently associated with being seropositive.  While 
most potential risk factors (such as shellfish consumption and water source) were non-
significant, we found a potential protective effect of being in the military and an increase 
in risk in immigrants who had spent 5-10 years in the United States. Finally, we saw a 
significantly higher seroprevalence in non-Hispanic Asians that was roughly twice the 
national average and significantly lower seroprevalence in all Hispanics. While age and 
immigration associations have hypothesized reasons, the cause for associations of 




Comparison of Hepatitis E Immunological Assays using 
NHANES III Sera 
Synopsis 
In 2008, the seroprevalence of Hepatitis E from the years 1988-1994 was estimated to 
be ~21%; whereas current estimates of seroprevalence are as low as ~6%. While it is 
possible that the drop is real, the use of different assays in the two time periods may 
also contribute to the apparent drop in seroprevalence. This paper examines this the 
impact of differing Hepatitis E serologic tests and their impact on the reported 
seroprevalence over several decades in the United States.   
This paper utilizes the NHANES III and continuous NHANES dataset, which 
encompasses the entire US population from 1988-1994 and 2009-2016, respectively. 
We examined the outcome of lifetime seroprevalence (IgG) with four assays – an in-
house assay, the DSI ELISA kit, a Wantai ELISA and a Wantai Western Blot. Both 
standardization and survey weights were used to reconstitute the US population to 
estimate national seroprevalence. Agreement statistics were calculated to compare 
inter-test comparability. All analyses and seroprevalence estimations were conducted in 
R. 
Using the in-house assay, the seroprevalence was 21%, but when using the more 
recently performed assay – DSI-EIA – the seroprevalence was 16%. We also observed 
significant differences in Cohen’s Kappa and relative sensitivity and specificity between 
assays, demonstrating a lack of exchangeability of the tests when used for National 
serosurveys.  Furthermore, we observed minimal differences between the 
seroprevalence calculated through survey weights versus standardization methods when 
the samples were randomly selected. 
This study demonstrates that the decline in seroprevalence was real but likely overstated 
due to assay variability.  This highlights a need to develop a gold standard assay or to 
standardize existing assays when conducting national seroepidemiologic surveys. The 





Hepatitis E (HEV) was first reported in the United States in 1997, but has been present 
in the country for an unknown length of time 15. To characterize Hepatitis E exposure in 
the U.S. population as a whole sera was collected from its participants from 1988-1994 
83. By examining serological data from NHANES III, a baseline Hepatitis E prevalence 
can be estimated for the early 90’s. These data can then be used to establish a long-
term trend of Hepatitis E seroprevalence. This trend data could better inform and identify 
potential factors affecting the changing seroprevalence on the U.S. population. One 
challenge is the lack of a standardized assay for Hepatitis E. This impacts the direct 
comparison of the data derived from the 1988-1994 sera and from more recently 
collected sera. The 1988-1994 sera were originally analyzed using an in-house assay. 
Further analyses of smaller subsets of the original 1988-1994 sera were conducted 
using a variety of HEV tests 84 85. The purpose of this study is to examine the 
seroprevalence of Hepatitis E from 1988-1994 using different assays; in addition, this 
study will examine the agreement between the assays. 
 
While various serological assays such as recomWell, DS-EIA, Anti-Hepatitis E virus 
ELISA by Euroimmun, Wantai, and DiaPro are available for use, there is no gold 
standard for detecting a past Hepatitis E infection. Without a gold standard, multiple 
tests are used interchangeably. Currently there is a move away from using in-house 
assays 37 and less viable commercially available kits. In 2008, an in-house immunoassay 
was used 83; the results of this assay were used in the paper that determined the 
seroprevalence was 21% despite the assay being uncharacterized 75. In 2013 and 2016, 
the sera was re-analyzed – though the findings were not published – using the DS-EIA-
ANTI-HEV-G/M assay 84 and the Wantai IgG and Western blot, respectively.  
 
These tests have not been well-characterized in the literature and divergent results 
document either no difference 36 or a significant difference 41. In the absence of a gold 
standard test, data cannot conclusively determine which test has superior sensitivity or 
specificity. We propose to compare an in-house assay with three commercially produced 
tests: DSI, Wantai ELISA and Wantai Western Blot. DSI is primarily used in the United 
States, and Wantai are commonly used in countries outside the United States.  
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It is especially important to compare the DSI assay from NHANES III to the DSI assay in 
the present study because previous studies found a large difference in the 
seroprevalence between the recent NHANES cycle that used the DSI assay and the 
NHANES III that used the in-house assay. If such a large difference truly exists, it would 
be difficult to explain without a substantial unknown risk factor or cohort effect – both 
potentials hold public health significance. As such, this study investigates the differences 
between the two assays used and the implications. If the difference in the tests can 
explain the difference between NHANES III and continuous NHANES, it will necessitate 
a discussion in the field regarding how reliable the IgG is for estimating seroprevalence. 
However, if the difference in tests cannot explain the difference between NHANES III 
and continuous NHANES, it would reveal that despite the aging population in the U.S., 





The population being examined are primarily from NHANES III, conducted in years 
1988-1994. To a lesser extent, data will be used from continuous NHANES years 2009-
2014. Both NHANES studies were conducted by the National Center for Health Statistics 
branch of the U.S. Center for Disease Control and Prevention. The source population 
covered is the entire United States, but the sample collected is clustered at multiple 
stages and stratified. The resultant sample contains measures and weights to 
reconstitute a simulation of the U.S. population. Hence, the data collected by the 
NHANES is representative of the entire non-institutionalized, civilian, resident U.S. 
population 69. To efficiently compare the Hepatitis E assays, the NHANES III sera were 
successively sub-setted (i.e. everyone tested by Wantai IgG were tested by all other 
assays; figure 2), so it is not known how well the sera tested by each assay represents 
the U.S. population. 
Variables- 
The variables examined in this study include the four different serological tests used to 
evaluate NHANES III sera for Hepatitis E antibodies. The DSI-EIA-ANTI-HEV-G assay 
was used to test continuous NHANES sera for Hepatitis E 40. The tests being compared 
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are the 1) NHANES in-house immunoassay, 2) the DSI-EIA-ANTI-HEV-G assay (DSI, 
Italy), 3) the Wantai HEV-IgG ELISA (WANTAI, China), and 4) an anti-HEV Western Blot 
(WANTAI, China). 
 
In-house IgG Immunoassay: This test was developed at the National Institute of Health 
specifically for the NHANES III study. The antigen used in the assay is a truncated 56 
kDa recombinant HEV capsid protein (ORF2) expressed in insect cells. This, or an 
assay using similar mechanisms have been used in other studies including those 
examining Hepatitis E vaccine efficacy. The sera examined by this assay were tested 
once, and all tests were performed by the one technician.  The sera was declared either 
positive or negative with no indeterminate classification 83. This assay was used on 
18,695 randomly selected sera from the original NHANES III sample. (Fig 2) 
DSI-EIA-ANTI-HEV-G/M assay: This test was developed by Diagnostic Systems Italy   
The assay uses a mix of ORF2 and ORF3 recombinant antigens sourced from 
genotypes 1, 2, and 3 of HEV and grown from mouse cells?. 41. The sera was declared 
either positive or negative with no indeterminate classification 40. This assay was used 
on 5,966 randomly selected sera from those tested with the In-House assay. This is also 
the assay used in the continuous NHANES cycles. (Fig 2) 
Wantai HEV-IgG ELISA: This test was developed in by Wantai and is sometimes known 
as Axiom. The assay uses the recombinant carboxy terminal of ORF2 sourced from 
genotype 1 for an antigen and grown in an unknown animal. 41 The sera was declared 
either positive or negative with no indeterminate classification 86. This assay was used 
on 1,803 non-randomly selected sera from those tested with the DSI-EIA assay. (Fig 2) 
Anti-HEV Western Blot: A western blot differs from the above assays in that it uses an 
electric pulse along with proteins to interact with your protein of interest to separate 
proteins by mass and charge. Through separating the proteins, one can identify 
individual proteins by purification or by using a reference. The details of the specific 
western blot used are not presented in the NHANES codebook. The sera was declared 
either positive or negative with no indeterminate classification 86. This assay was used 





NHANES III Re-analysis & Comparison- 
In order to compare the performance implications of using a given Hepatitis E assay, two 
sets of analysis will be done: 1) establish the seroprevalence from 1988-1994 under the 
different assays, 2) compare the assays used by calculating an agreement statistic. Data 
analysis will be done using R 3.3.2 with the Hmisc, dplyr, survey, epitools and 
CompareTests 87 libraries. Both data from NHANES III and continuous NHANES will be 
used. All four IgG assays done in NHANES III will be included: the in-house IgG assay, 
the DS-EIA-ANTI-HEV-G assay, the Wantai IgG, and the Western blot; however, the two 
Wantai assays were conducted on a non-random subset of the data, so they will not 
produce accurate seroprevalence estimates.  
 
Seroprevalence Estimation: 
The first analysis will be to compare the estimates of seroprevalence derived from using 
one of the four different IgG assays. There will be two methods of analysis to determine 
the seroprevalence of Hepatitis E in the NHANES III data: the first is to assume the 
survey weights are still valid and use code standard for complex survey design; the 
second is to disregard the survey weights because they may no longer be applicable to 
the subset of sera used in the assays and instead use standardization. 
 
Seroprevalence Analysis using Survey Weights: 
NHANES III data will be used as complex survey data, using packages to account for 
the clustering, stratification, etc. This analysis may produce inaccurate seroprevalence 
estimates for the NHANES III data – especially for the assays which only were 
performed on a small subset of the original data.   
To establish a seroprevalence that is directly comparable to the continuous NHANES, 
we will use the svydesign function from the survey library in R. The svydesign function 
allows for the use of complex survey design data to obtain estimates from the population 
data. Like the continuous NHANES data, NHANES III data contains weights to make it 
representative of the U.S. population, but the NHANES III data does not contain the 
clusters or strata present in the continuous NHANES data. The results will be presented 
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in terms of the proportion of people testing positive for long-term exposure (using the 
IgG tests and the Western Blot). 
 
Seroprevalence Analysis using Standardization: 
NHANES III data will be standardized to a reference population using the 
ageadjust.direct function from the epitools library. Standardization was used to simulate 
the 2016 U.S. population on basis of age and race. While this method may not yield 
results directly pertinent to the current U.S. population or the U.S. population at the time 
of NHANES III, it will likely be more accurate in simulating how the different assays 
would apply to a theoretical population. This is especially pertinent to the assays which 
were only performed on a small subset of the NHANES III because it is not known how 
representative the subset was of the original complex survey methodology – i.e. the 




In addition to estimating the seroprevalence, we will compare the performance of the 
different assays on the same individuals. Because all assays used nested subsets of the 
same NHANES III population (i.e. all persons tested with the Wantai assay were also 
tested by the in-house assay), we can directly compare the tests. One key advantage of 
doing test comparisons is they do not rely on the assumption that the tests were 
conducted on similar populations. 
To determine the inter-assay reliability, we will use the CompareTests function from the 
CompareTests library in R. Apart from the in-house assay initially used and the DS-EIA-
ANTI-HEV-G assay, two other comparable assays have been used on NHANES III sera: 
Wantai HEV-IgG ELISA and Anti-HEV Western Blot; the DS-EIA-ANTI-HEV-M assay is 
the only test that examines short-term exposure so will not be included in the analysis. 
Using CompareTests, a kappa coefficient will be calculated to determine how similarly 
the tests performed on a 1-1 basis. A ĸ of 0.8 or greater is considered a strong 
agreement 88. In addition, we will calculate the sensitivity and specificity of the three 




This analysis has the advantage of bypassing the complex survey design issues seen in 
the seroprevalence analysis, such as incorrect weights. Because we assume there is no 
interaction between test performance and demographic groups and we are not 
concerned with population statistics, the weights and measures can be safely 
disregarded in this analysis. However, this means that the analysis cannot detect 
potential demographic biases in test performance and the inferences drawn would be 
difficult to apply to subsets of the population. Another drawback with this analysis plan is 
there is no established gold standard. We can say if a test produces on average more 




Estimated Seroprevalence using Survey Weights 
Table 8 shows the estimated U.S. seroprevalence using the NHANES III data and the 
NHANES 2009-2016 data calculated by using the recommended survey weights. The 
seroprevalence estimates by the in-house assay (20.8%) and the DS-EIA (16.5%) are 
statistically significantly different from one another.  The Wantai and the Western blot 
were done on a non-random subset of the sera tested by the DS-EIA kit and hence 
cannot be used to infer the true U.S. seroprevalence. 
 
Estimated Seroprevalence using Standardization 
The estimated U.S. seroprevalence using the NHANES III data and the NHANES 2009-
2016 data calculated by standardizing to an approximation of the 2016 U.S. population 
on age and race are shown in Table 9. The estimates of seroprevalence and 
conclusions align with the survey weighted methods above (~20% for the in-house and 
~16% for the DS-EIA). For the estimates derived from random subsets of the NHANES 
III sera, the estimates differ by fractions of a percent; the estimates of the 2009-2016 
change to a similar degree.  
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Estimates taken of non-random subsets did differ significantly between the survey 
weight method and the standardization method. The estimates changed by ~10% and 
were found to be statistically significant.  
 
Relative Sensitivity & Specificity  
The relative test sensitivities are displayed on Table 10. The in-house assay had a high 
sensitivity when assuming any of the other assays were the gold standard, but other 
tests had a wide range of sensitivities when tested against it as the gold standard (48-
86%). Conversely, the DS-EIA assay had consistently low sensitivity (48-62%) and other 
tests had a high sensitivity when compared against it (96-97%).  
Table 11 shows the relative specificity. When using any other assay as the gold 
standard, the in-house assay low specificity (38-79%), whereas the DS-EIA had a 
consistently high specificity (94-99%). The Wantai ELISA had variable specificity (42-
88%), and the Wantai western blot had similarly variable specificity (54-85%). 
These tables also provide information when their results are combined; for example, if 
we take the in-house EIA as the gold standard and the Wantai assay as the referent we 
find the sensitivity is 86% and the specificity is 88%; but when DS-EIA is the referent, we 
see a sensitivity of 48% and a specificity of 99%.      
 
Kappa Scores 
Table 12 shows the Kappa agreement score. All tests when compared to each other 
performed better than chance (ĸ>0); however, there still was significant disagreement. 
The DS-EIA and the Wantai had roughly similar agreement statistics when they were 
compared to the in-house assay (ĸ~0.55) 88. The agreement statistic for the DS-EIA vs 
Wantai was weaker (ĸ~0.35). The strongest agreement statistic observed was when 
comparing the Wantai ELISA with the Wantai Western Blot (ĸ~0.64) – still fall short of a 






Discussion of seroprevalence estimates 
We observed that when using the DS DSI-EIA applied to NHANES III sera, the 
seroprevalence of HEV IgG was 16.2%, a significant departure from the previous 
estimate using the in-house assay (20.9%) and trending towards, but still distant from 
modern DS DSI-EIA estimates of ~6%. This documents that the NHANES III reports of 
seroprevalence and the more recent reports of seroprevalence were only partially due to 
differences in assay methods.  
While the two assays produced by Wantai cannot be used to determine seroprevalence 
due non-random sampling, the sensitivity and specificity analyses suggest the 
seroprevalence estimate would be between the DS DSI-EIA and the in-house assay. 
The substantial difference found between the assays’ estimates of seroprevalence 
illustrates the necessity of more uniform testing of Hepatitis E.  
 
Discussion of survey weights vs standardization 
There were minimal differences between using survey weights of randomly subsetted 
data and standardizing the randomly subsetted data in terms of seroprevalence. This is 
suggestive that survey weights remain valid even when applied to a subset of the 
original dataset. The DS DSI-EIA was performed on less than 20% of the NHANES III 
participants (5,966 of 33,994 people were tested). This paper does not identify the point 
at which the survey weights become unreliable in their estimate. 
Significant differences appeared between the two methods when the data was non-
randomly subsetted. In this case, the standardization method resulted in more realistic 
results. The standardization method reported a highly unrealistic seroprevalence 
because selection was done based on test results; it remains to be seen how well 
standardization can estimate a parameter when the data is from a non-random subset of 
a larger dataset and the outcome is not a factor in the selection. 
 
Discussion of Test differences 
In this study, we found highly discordant results between four assays used to analyze 
the data. The two most similar tests were developed by the same company, Wantai, but 
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used different techniques; one was an ELISA and the other was a Western Blot. The in-
house assay and the DSI DS-EIA were also ELISAs. ELISA assays may differ for many 
reasons, most notably by which part of which protein it is detecting, but also what 
threshold of signal qualifies as a positive result.  
 
This is the first seroepidemiologic study to examine differences between commercial 
Hepatitis E kits. In previous studies, the population is either clinical subjects, of which a 
large subset is suspected to have HEV 36; or a mix of blood donors and people 
suspected to have been infected with HEV 41. This study examines a general population 
without respect to previous HEV infections. The general population has a far lower 
seroprevalence than people suspected to have HEV, as such the decrease in quality of 
the agreement statistic between this study is likely due to the test being designed as a 
clinical test, not an epidemiological screening tool. The poor performance in a low 
seroprevalence population is also indicative of poor specificity and poor positive 
predictive value; it can be inferred that tests with generally low specificity as compared to 
the other tests value sensitivity more than specificity. This appears to be the case with 
the Wantai products, as it has also been found in previous studies that they potentially 
give a higher rate of false positives and less false negatives 37.  This does not mean any 
of the assays examined in this paper are not suitable for clinical settings, rather more 
attention to specificity should be given when conducting population-level investigations. 
Of the tests done, the DS-EIA appeared to have the highest specificity, so may be the 
most appropriate in a population context, its high specificity is also supported by 
previous studies 41.  
 
The Cohen’s Kappa score of 0.35 between DS-EIA-ANTI-HEV-G and Wantai HEV-IgG 
ELISA represents significant disparities between the major commercial packages for 
Hepatitis E serology. In addition, the previous analysis of NHANES III sera significantly 
overestimated the seroprevalence of Hepatitis E. While the seroprevalence between 
NHANES III and the continuous NHANES have been found to more similar than 





Due to the retrospective nature of this study, there were several limitations embedded in 
the data. One of the most significant limitations is only two of the major immunological 
assays were used. Several other relevant kits exist but were not used in testing the sera. 
The assays used were designed for clinical use, not epidemiologic surveys which may 
contribute to an inflated seroprevalence estimate. Further, some of the methodological 
details of the assays used were not reported, so changes to the assay protocol may 
have been made. The assays were conducted on consecutive subsetting of the original 
NHANES III data – while this study demonstrated that the subsetting at random was 
unlikely to significantly alter the estimates, a sample that had survey weights constructed 
for it would yield more accurate results. Finally, the subsetting used for the Wantai assay 
was non-random, so while sensitivity and specificity could be calculated, the 
seroprevalence estimates are severely biased. 
Future Directions 
Though we have provided further evidence that there has been a decline in Hepatitis E 
seroprevalence in the 15 years, we have not determined potential reasons for the 
decline. One possibility is previous age cohorts in the United States had higher 
seroprevalence due to a change in risk factors. While Hepatitis E is not thought of being 
waterborne in the United States, it could have been prior to public efforts to secure safe 
drinking water. The decreasing prevalence may be due to a decrease in waterborne 
disease in general in the United States 89. A future study could compare declining trends 
of waterborne disease and foodborne disease across the 20th century to identify if either 
could explain the decline in Hepatitis E. 
Further research is required in comparing the performance of the various Hepatitis E 
assays or perform a systematic review of the current literature pertaining on test 
performance in clinical and seroepidemiologic contexts. Ultimately, a gold standard for 
HEV infection must be established. 
Conclusion 
This study examined NHANES III serological samples tested with an in-house assay, a 
DSI kit, and two Wantai kits. We found significant deviations from the previously reported 
seroprevalence of ~21%, and now believe the seroprevalence in that time period is 
~16%. While this change is significant, it is still far from the current seroprevalence 
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estimates of ~6%. The study found significant deviations in critical test attributes leading 
to the conclusion that in epidemiologic studies, the tests cannot be used 
interchangeably. We also determined there is minimal difference in parameters of a 
subsetted dataset in using standardization versus using native sampling weights when 




Liver Biochemistry in Persons Recently Infected with 
Hepatitis E Virus 
 
Synopsis 
The seroprevalence of Hepatitis E virus infection (HEV) in the United States is 
approximately 6%. While most of these cases are asymptomatic, the liver pathology of 
HEV is under-investigated. This study uses NHANES data containing over 10,000 
subjects to assess the hypothesis that subclinical HEV can influence liver health. Two 
primary analyses were done: testing an association between HEV IgM and ALT – a 
marker of liver inflammation; and testing an association between HEV IgG and Fib-4 – a 
composite score reflecting potential liver fibrosis. These analyses were repeated in 
populations at risk for liver damage. The results found null results for the hypotheses 
tested. This is the first study examining predominantly subclinical effects of HEV 
infection in the United States, while studies have been conducted elsewhere, they have 
either been conducted in specific populations at risk for liver damage, or they focus on 
individual cases. The conclusions are suggestive that, in the general U.S. population, 
predominantly asymptomatic HEV infections do not contribute to the overall burden of 
liver disease and does not cause sustained liver inflammation. 
 
Introduction 
Hepatitis E is endemic to the United States, but its prevalence and impact remain 
unknown. Hepatitis E was discovered in the 1980’s; and was only discovered in the 
United States in 1997. Between 1997 and 2008, Hepatitis E was generally not 
considered a major threat due to the typically asymptomatic self-resolving presentation 
of the only genotype found in the U.S. However, when the possibility of chronic infection 
by hepatitis was discovered in 2008, Hepatitis E was studied in more depth. Chronic 
Hepatitis E is typically defined as an active replication of the HEV infection lasting more 
than 3 months. A chronic infection is more likely to cause serious illness or death in 
immunocompromised persons than an acute infection. While the causal strain is 
endemic in the U.S., chronic Hepatitis E is primarily seen in Europe. Recent studies 
have reported Hepatitis E virus (HEV) to infect non-hepatic cells, such as neurons 90 and 
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have established the potential for a latent HEV infection to reactivate 91. Further research 
is needed to better understand how HEV interacts with the body, especially the liver, 
outside of the context of what we recognize as HEV infection in terms of signs and 
symptoms. 
Symptomatic cases of HEV infection typically present in an acute fashion – lasting 
approximately a month – and have different progressions depending on the genotype of 
the virus. The most prevalent genotypes worldwide are genotypes 1 and 3. Genotype 1 
is found in resource-limited countries with unsecure water supplies whereas genotype 3 
is found globally. Genotype 1 is more virulent than genotype 3, and can evolve into liver 
failure, especially in pregnant women. Genotype 3 infection can become chronic 
particularly in immunosuppressed individuals 63 30. Despite the difference in progression 
and virulence, the symptoms induced by both viral genotypes are similar. Symptoms of 
acute infections may include fever, anorexia, arthromyalgia, pruritus, dark urine, 
diarrhea, nausea, headache, abdominal pain, asthenia, vomiting, purpuric rash and 
jaundice; these symptoms are mainly related to hepatic inflammation and last from a few 
days to a month or more 25 26 27 28. In addition, both types of Hepatitis E are associated 
with increases in markers pertaining to liver inflammation; such as, serum alanine 
transaminase (ALT), aspartate aminotransferase (AST), bilirubin, alkaline phosphatase, 
and γ-glutamyltransferase 29 30. These signs and symptoms have been clearly described 
in the literature for symptomatic infections, but most infections in the U.S. are 
asymptomatic. 
While HEV infection is commonly asymptomatic in the U.S., subclinical manifestations of 
HEV infection in asymptomatic cases can occur. As testing for Hepatitis E is not routine, 
detecting asymptomatic cases is unlikely in a clinical setting. Therefore, studies 
examining subclinical HEV infection either need to be specifically designed to detect 
subclinical infections or rely on large surveys that include HEV assays. 
Previous studies have attempted to examine HEV in asymptomatic people. One study 
examining a population that had either dialysis or organ transplants in Argentina found a 
change in liver enzymes (i.e. AST and ALT) in seropositive HEV patients, but did not find 
symptoms associated with HEV 92. A similar study conducted in southern Italy found 
much higher ALT levels in persons testing positive on IgM assay for HEV – while those 
testing positive on IgG did not have significant findings 93. A study conducted in 
Germany followed ALT levels of 10 blood donors with asymptomatic HEV infection and 
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found half of them had elevated ALT levels 94. Finally, a study conducted in Nepal found 
HIV positive persons who also had evidence of a prior HEV infection had far higher 
indicators of liver fibrosis as compared to HIV positive persons who tested negative for 
HEV 95. 
This paper examines both potential short-term effects of Hepatitis E – liver inflammation 
– and potential chronic effects of Hepatitis E – liver fibrosis – using the National Health 
and Nutrition Examination Survey (NHANES). To determine liver inflammation, blood 
tests can be reliably used. The gold standard tests for examining liver fibrosis requires 
an examination of the liver, but NHANES does not conduct liver examinations directly. 
NHANES conducts a biochemistry panel that contains assays that can be used to 
estimate liver inflammation or damage – including tests measuring aspartate 
transaminase (AST), alanine transaminase (ALT), and platelet count. These tests can be 
used together to project whether someone has liver fibrosis or other forms of liver 
disease when using the Fib-4 score or the NAFLD score, respectively. 
The NHANES data contains a biochemical assay containing the above measures of liver 
function. NHANES also measures antibodies IgG and IgM through a blood test; IgG 
detects whether a person has ever been infected with HEV whereas IgM detects 
whether a person has been infected with HEV within the recent past (approximately 6 
months). As IgM indicates a recent infection, the data can be used to determine if there 
is a change in liver inflammation – indicated by an increase in serum ALT – following an 
infection of HEV. The IgM assay cannot distinguish between symptomatic HEV 
infections and asymptomatic HEV infections, but the low rate of symptomatic cases 
ensures the overwhelming majority of cases in NHANES are asymptomatic. So, by 
examining patients with positive IgM, we should be able to draw inferences for 
asymptomatic cases. This paper has two primary analyses: first examining IgM status in 
relation with ALT; second, using IgG and Fib-4 to determine if there is an increased risk 
of fibrosis in persons who had been infected with HEV. The latter analysis uses the IgG 
data rather than the IgM data because unlike inflammation, fibrosis is advanced damage 
to the liver that can become permanent. 
Two sets of supplemental analyses were also conducted. The first supplemental 
analysis examined ALT in likely recent or active infections by examining participants with 
positive IgM but negative IgG. IgG antibodies takes longer to activate than IgM 
antibodies, hence examination of people with only IgM positive and not IgG positive sera 
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could indicate someone with an active or highly recent infection. The second set of 
supplemental analyses were examining ALT and Fib-4 among those with pre-existing 
liver conditions: other hepatic viruses, diabetes, heavy alcohol consumption, and 
unspecified liver conditions. 
Methods 
Population 
The population being examined was from NHANES years 2009-2016. NHANES is 
conducted by the National Center for Health Statistics branch of the U.S. Center for 
Disease Control and Prevention. The source population is the entire United States, but 
the sample collected is clustered at multiple stages and stratified. The resultant sample 
contains weights to reconstitute a simulation of the U.S. population. In this way, the data 
collected by the study is representative of the entire non-institutionalized, civilian, 
resident U.S. population 69.  
 
Variables 
Analysis in General Population 
The primary exposure variable in this study was presence or absence of HEV in serum 
ascertained by the DSI DS-EIA-ANTI-HEV-G/M assay. This assay was used to 
determine HEV infection in the continuous NHANES study. Results from the assay are 
characterized as positive or negative. This study compared IgG and IgM presence or 
absence to clinical laboratory results. A positive IgM titer represented recent infection 
and a positive IgM titer in the presence of a negative IgG titer represented an acutely 
recent infection. A positive IgG titer represented an infection in the past.  These were 
used to assess inflammation analyses comparing ALT as an outcome for liver 
inflammation and Fib4 to measure liver fibrosis as the outcome. 
Alanine aminotransferase (ALT) is found mainly in the liver’s parenchymal cells. It 
catalyzes two steps of the alanine cycle – a process that cycles nutrients between the 
skeletal muscles and the liver. A normal range in female adults is ≤ 34 IU/L and ≤ 52 
IU/L for male adults (although these values might vary); an elevated ALT level suggests 
damage to the liver – such as that seen in viral hepatitis.  
The Fibrosis-4 (Fib-4) score estimates scarring of the liver. It is calculated by multiplying 
age by AST level, then dividing that by the platelet count multiplied by the square root of 
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the ALT level. For detecting moderate or advanced fibrosis, a cutoff of >1.0 gives a 
sensitivity of 64.5% and a specificity of 57.1%; for detecting advanced fibrosis, a cutoff of 
>1.45 gives a sensitivity of 70.0% and a specificity of 73.7% 96. 
Potential confounders present in all analyses included were: age, gender, and 
race/ethnicity. Age was measured continuously up to age 80; people who were age 80 
or greater were marked as being 80 for the analysis. Gender was characterized as male 
or female. Race/ethnicity was characterized as Mexican American, other Hispanic, Non-
Hispanic white, Non-Hispanic black and other race (including multiracial).  
Additional confounders include other liver conditions, alcohol consumption, injection drug 
use and/or diabetes. Persons with other liver conditions consists of a composite of 
persons with Hepatitis B infection, Hepatitis C infection, high NAFLD scores3, or were 
self-reported in a questionnaire. Alcohol consumption was measured continuously as 
self-reported drinks per day. Diabetes condition was marked as present if the individual 
self-reported a doctor categorizing them as having diabetes or borderline diabetes. 
Injection drug use was also analyzed as self-report response of yes or no. 
The outcome variables in the study include ALT measured continuously in IU/L and 
Fibrosis-4 measured binomially with a cut-off for a Fibrosis score of 1.45 which would 
strongly suggests advanced fibrosis 96.  
Analyses in High Risk Population 
Like the general population analysis, serum titer was ascertained by the DSI DS-EIA-
ANTI-HEV-G/M assay. Potential confounders present in all analyses included were: age, 
gender, and race/ethnicity. Age was measured continuously up to age 80; people who 
were age 80 or greater were marked as being 80 for the analysis. Gender was 
characterized as male or female. Race/ethnicity was characterized once as Mexican 
American, other Hispanic, Non-Hispanic white, Non-Hispanic black and other race 
(including multiracial).  
Variables used define the high-risk subgroup include persons with other liver conditions 
(including NAFLD or other Hepatitis infections), heavy alcohol consumption, injection 
                                                          
3 The Non-Alcoholic Fatty Liver Disease (NAFLD) score – or NAFLD fibrosis score (NFS) – 
separates NAFLD patients with advanced fibrosis from those without advanced fibrosis. The 
score is calculated using age, hyperglycemia, body mass index, platelet count, albumin, AST and 
ALT. (Angulo et al., 2007) Clinically, NFS has been shown to be cost-effective through stratifying 
patients according to their level of need (Tapper, Hunink, Afdhal, Lai, & Sengupta, 2016). 
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drug use and/or diabetes. The variables included are similar to the general analysis but 
are coded categorically to define the subgroup. 
A person would be defined as having other Hepatitis infections if either their Hepatitis B 
or C4 tests were positive – the Hepatitis B serological test we used was the surface 
antigen test, and Hepatitis C infection was determined through RNA tests. Persons with 
other liver conditions were detected by questionnaire – analyzed as yes or no. We 
assessed probable NAFLD using the NAFLD fibrosis score binomially using 0.676 as the 
cutoff between a high NAFLD score and a medium/low NAFLD score. Heavy alcohol 
consumption was defined as having an average of 2 or more drinks per day or having 
had had more than 50 days in the last 12 months of drinking more than 4 and 5 drinks 
per day – for women and men, respectively. Diabetes condition was marked as present 
if the individual reported a doctor categorizing them as having diabetes or borderline 
diabetes. Injection drug use defined as self-report response of yes. 
The outcome variables in this analysis are the same as that used in the above general 
population analysis. 
Statistical Analysis 
All analyses were done using “R” 3.3.2 with Hmisc, dplyr, lme4 and survey libraries. 
Participants without HEV serology data or biochemical exams were removed from 
analysis. There was no single primary outcome variable as both ALT and Fib-4 were 
used. NHANES uses a complex survey design that has multiple clusters, employs 
stratification, and oversamples certain demographic groups. These methods are 
essential for conducting the survey efficiently through narrowing the geographic scope 
from the entire U.S. to a small proportion of the counties, but they are a deviation from a 
simple random sample – the basis of many statistical techniques. As such, these 
methodological decisions were accounted for to obtain unbiased estimates and accurate 
standard deviations. 
 
The survey library contains functions to process survey design data and to properly 
analyze the survey design data. NHANES provided variables for clusters (sdmvpsu), 
                                                          
4 Hepatitis A not included because it is acute, meaning it has very low potential for a co-infection 
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strata (sdmvstra) and weights (wtmec2yr)5. Once the survey weights, strata, and clusters 
were all accounted for by using the svydesign function, the analyses were performed. 
 
ALT Analysis in General Population 
Multivariate linear regression was used to examine possible associations of HEV 
infection with liver inflammation. When assessing potential liver inflammation with ALT, 
the primary exposure variable for seropositivity was IgM positivity. ALT reported 
continuously to measure inflammation, and IgM status was analyzed binomially. An 
additional analysis examined IgM positivity in the presence of negative IgG. Age, 
race/ethnicity, gender, known liver conditions, alcohol consumption, diabetes, and 
injection drug use were included in both models as potential confounders.  
 
Fib-4 Analysis in General Population 
When assessing potential long-term liver damage with Fibrosis-4, the primary exposure 
variable for seropositivity was IgG. Fibrosis-4 was reported categorically with the cutoff 
for high chance of fibrosis being 1.45, and IgG status was analyzed binomially. Age, 
gender, known liver conditions, alcohol consumption, diabetes, and injection drug use 
were included as potential confounders. A linear model with similar parameters was also 
run to identify more subtle changes in Fib-4. 
 
Analyses in High Risk Population 
The primary inflammation analysis and the fibrosis analysis were repeated in persons at 
higher risk of liver disease. This high-risk group included people: with other liver 
conditions (including other hepatitis infections and NAFLD), with heavy alcohol 
consumption, who have used injected drugs, and people with diabetes. Because many 
of the confounders in the initial analyses were used to define the high-risk group, the 
only confounders in these models were age, race/ethnicity and gender. 
 
                                                          
5 wtmec2yr can only be applied for analysis of a single 2-year cycle of NHANES. These weights 
were converted to 8-year weights (wtmec8yr) by dividing each cycle’s weights by 4 for analysis of 






The population demographics and other characteristics of the population analyzed with 
weights applied and shown on Table 13. Table 13 also contrasts the characteristics of 
those in the population testing positive on the HEV IgG assay to those testing negative 
on the assay. Notably, there were some substantial differences in this univariate 
estimation of HEV infections, most critical among them being those infected with HEV 
were on average ~20 years older than those who had not been infected. BMI was higher 
in the persons who were HEV IgG positive (29.1 vs 27.6). In addition, there were 
significant racial differences; non-Hispanic black persons and Hispanics who are not 
Mexican Americans were less likely to have been infected whereas non-Hispanic whites 
and other non-Hispanic persons were more likely to have been infected.   
Clinical Signs 
HEV IgG was also predictive for some clinical signs. People who tested positive for HEV 
IgG were also much more likely to test positive for HEV IgM (6.1% vs 0.7%). 
Additionally, Fib4 and NAFLD scores were elevated in the presence of positive HEV IgM 
(1.56 vs 1.03 and -1.19 vs -2.16 respectively); however, ALT and albumin levels were 
similar between people testing positive for HEV IgG and people testing negative for HEV 
IgG.  
General Population Multivariate Analysis 
Liver Inflammation (ALT) 
Table 14 shows HEV IgM status tested against ALT. Testing positive for HEV IgM was 
associated with a non-statistically significant 0.22 decrease in ALT IU/L (95% CI: -4.17, 
3.72). While HEV IgM was not statistically significant, reporting having a previous liver 
condition was significant (IU/L: 9.44; 95% CI: 6.90, 11.99). Other factors that increased 
ALT levels were being male (ALT IU/L: 8.46; 95% CI: 7.70, 9.21), having Hispanic 
heritage (Mexican Americans: ALT IU/L: 6.48; 95% CI: 4.49, 8.28 and Other Hispanic: 
ALT IU/L: 2.97; 95% CI: 1.45, 4.48), and alcohol consumption (ALT IU/L: 1.24 per 
average daily drink; 95% CI: 0.74, 1.70). Non-Hispanic Blacks appeared to have a lower-
than-average ALT level (ALT IU/L: -2.07; 95% CI: -2.87, -1.28).  
50 
 
The analysis of HEV IgM positive where HEV IgG was negative is shown in table 15. 
This analysis found again no association between HEV IgM and ALT (ALT IU/L: -1.11; 
95% CI: -5.53, 3.32). The factors that influenced ALT in table 14 were similarly present 
in table 15 with similar effect sizes. 
Liver Fibrosis (Fib4) 
Table 16 shows HEV IgG status tested against high Fib-4 status in the general 
population. There was a small, but statistically significant increase in the likelihood of 
having a high Fib-4 score associated with testing positive on HEV IgG (RR: 1.03; 95% 
CI: 1.01, 1.05).  Other factors that increased risk of having a high Fib-4 score were being 
male (RR: 1.17; 95% CI: 1.05, 1.29), older age (RR: 1.08 per year; 95% CI: 1.08, 1.09), 
having other liver conditions (RR: 1.35; 95% CI: 1.24, 1.46), and high alcohol 
consumptions (RR: 1.04 per average daily drink; 95% CI: 1.02, 1.06). A similar model 
treating Fib-4 as a continuous variable did not find a statistically significant increase 
(0.05; 95% CI: -0.04, 0.14). 
 
High-Risk Population Multivariate Analysis 
Liver inflammation (ALT) 
Table 17 shows HEV IgM status tested against ALT in the high-risk population – persons 
with other liver conditions (including NAFLD or other Hepatitis infections), heavy alcohol 
consumption, injection drug use and/or diabetes. In this population, HEV IgM was not 
associated with increased ALT (ALT IU/L: 2.87; 95% CI: -5.19, 10.94). The other results 
were broadly similar to those seen in the model run in the general population (Table 15) 
with males, and Mexican Americans having higher levels of ALT; ALT IU/L: 6.78; 95% 
CI: 5.40, 8.15 and ALT IU/L: 4.49; 95% CI: 2.06, 6.92 respectively. However, there were 
some differences; Hispanic people other than Mexican Americans no longer appeared to 
have higher ALT levels (ALT IU/L:  1.90; 95% CI: -0.64, 4.43) and there was a 
statistically significant decrease ALT IU/L as age increased (ALT IU/L:  -0.12; 95% CI: -
0.15, -0.08). 
Liver Fibrosis (Fib4) 
Table 18 shows HEV IgG status tested against Fib-4 in the high-risk population. In this 
population, HEV IgG was not associated with high Fib-4 score (RR: 1.02; 95% CI: 0.98, 
1.06). The only variable found statistically significant was age (RR: 1.05; 95% CI: 1.05, 
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1.05). While being male was significant in the general population, it was no longer 
statistically significant in the high-risk population (RR: 1.05; 95% CI: 1.00, 1.11). Having 
had liver conditions and high alcohol consumption were not examined in this analysis 
because those variables were used to define this population. A linear multivariate 
analysis of Fib-4 also found a non-significant association with HEV IgG. 
 
Discussion 
Liver Inflammation (ALT) Findings 
Associations between HEV IgM and ALT were not found. Though there were no 
associations between HEV IgM and ALT, the ALT analyses found gender, liver disease, 
and alcohol consumption to be associated with higher levels of ALT. In addition, race 
was associated with ALT; Hispanics had substantially higher ALT score than non-
Hispanic whites, and non-Hispanic blacks having lower ALT than non-Hispanic whites. 
Age did not appear to influence ALT levels. These data demonstrate while some factors 
can increase liver inflammation levels, recent asymptomatic HEV infection does not. 
Liver Fibrosis (Fib 4) Associations 
We found a small association in both univariate and a log-scale multivariate model of 
HEV IgG and Fib-4 in the general population. The association in the univariate model 
was heavily confounded by age among other factors. The association in the log-scale 
multivariate model was small – having positive IgG increasing of a high Fib-4 score by 
approximately 3%. However, this association was not detected in the linear scale model 
or in any of the models using only the high-risk population. While these results are 
somewhat ambiguous, they clearly do not demonstrate a significant public health risk 
from seemingly asymptomatic HEV infections causing liver fibrosis. Apart from HEV IgG, 
other risk factors found for high Fib-4 score were not unusual – being male, being older, 




While the non-existent and weak associations between HEV infection and liver 
biomarkers are a departure from prior literature, this study was a cross-sectional study 
conducted in a healthy population. Though the studies conducted in Italy 93 and 
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Argentina 92 used the same kit as this study – DSI DS-EIA-ANTI-HEV-G/M – to detect 
HEV, these tests were conducted in clinical patients on hemodialysis and a combination 
of hemodialysis and organ transplant recipients, respectively. The study conducted in 
Nepal found a strong, positive association between HEV IgG and Fib-4, but it used a 
different kit, characterized the effects of a different genotype of HEV, and the study 
population was people infected with HIV 95. Though HEV co-infection with HIV does not 
increase the rate of chronic cases as frequently as HEV infection in persons with solid 
organ transplantation, other studies have found synergistic effects in co-infected persons 
97. These studies show that HEV in certain subpopulations can have meaningful effects 
on the liver, but there is conflicting evidence whether asymptomatic HEV influences 
health on a general population level.  
A study conducted in Germany was closest in scope and aims to our study 94. While both 
studies examined many samples of asymptomatic, healthy people, Vollmer et al. utilized 
PCR to track active infections, whereas in our study we used IgM to identify recent 
infection (i.e. a more sensitive but far less specific approach). Vollmer et al. identified 10 
persons with an active infection, but only 5 persons had substantial increases in ALT. 
While Vollmer demonstrated that acute liver inflammation is possible in asymptomatic 
infections of HEV, this study suggests the inflammation caused by acute, asymptomatic 
HEV occurs too infrequently and too briefly do be detected in those testing IgM positive. 
Limitations & Future Directions 
This study suggests HEV is unlikely a cause of liver inflammation or liver fibrosis in the 
U.S. general population. The null findings for inflammation could be explained by the IgM 
not being designed for population surveys; even with good specificity, the positive 
predictive value of IgM would be low due to the extremely low prevalence of positive 
IgM.  This low PPV would dilute an effect of IgM on ALT. The weak/null IgG findings re-
enforces the hypothesis that asymptomatic HEV does not have cause sustained liver 
inflammation. This conclusion is more certain than the conclusion of IgM because the 
prevalence of IgG is substantially higher than the prevalence of IgM, reducing the 
proportion of false positives. Despite not finding higher risk of liver inflammation or liver 
fibrosis in the high-risk population, this still warrants further investigation in 





Overview of goals: 
The goal of this dissertation was to quantify and characterize Hepatitis E virus (HEV) 
infections in the United States over the past 30 years but with a special focus on 2009-
2016. In the first paper, I used NHANES 2009-2016 data to examine seroprevalence in 
both the general U.S. population and in specific demographic groups. In addition, I used 
this data to examine potential risk factors of Hepatitis E seropositivity identified in 
previous literature. In the second paper, I used NHANES III data to compare the 
performance of three different ELISA assays and one Western Blot used to diagnose 
HEV infection. In the third paper, I used NHANES 2009-2016 data to determine if 
subclinical HEV infection has acute or chronic liver pathology. 
Summary of findings: 
Paper 1 – Seroprevalence 
We found HEV infections to be common, with seroprevalence in the general population 
being stable at around 6.1% from 2009-2016. There did appear to be a significant 
upwards trend in HEV seroprevalence associated with age. Non-Hispanic Asians had 
unexpectedly high average seroprevalence (12.8% vs the national average of 6.1%). 
Asians born outside of the U.S. seem to be driving the trend of higher HEV 
seroprevalence for their racial group. In general, people born outside of the U.S. have 
higher seroprevalence, suggesting foreign acquired cases of HEV is a significant 
contributor to the overall national seroprevalence in the U.S. In terms of the second goal, 
the study did not find evidence of an association between HEV, unsafe water use, 
shellfish, or blood-born transmission; but these cannot be excluded as potential risk 
factors. 
Paper 2 – Test Comparison 
When using the NHANES III data from 1988-1994 to compare the various diagnostic 
tests, we observed substantial differences between the assays’ results. When using the 
DS DSI-EIA – the assay used in NHANES 2009-2016 –, the seroprevalence of HEV IgG 
was 16.2%, a significant departure from the previous estimate using the in-house assay 
(20.9%). Beyond the seroprevalence estimates, we found highly discordant results 
between four assays used to analyze the sera. The highest kappa agreement score was 
between two kits both produced WANTAI and was 0.64 – still not a strong kappa score. 
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Between two commonly used kits DSI EIA and WANTAI ELISA the kappa agreement 
score was only 0.35, which is typically thought of as a ‘fair’ kappa score. 
 
Paper 3 – Subclinical Manifestations 
When looking for subclinical manifestations of HEV infection, we found a small 
association in both univariate and a multivariate model of HEV and Fib-4 (an indirect 
measure of liver fibrosis). The association in the log-scale multivariate model was small 
– having positive HEV IgG increases the chance of having a high Fib-4 score by 
approximately 3%. This association was not detected, however, in the linear scale 
model. Associations between HEV IgM and ALT were not found. Apart from HEV IgG, 
other risk factors found for high Fib-4 score were not unusual – being male, being older, 
having liver disease, and higher alcohol consumption all contributed to a higher Fib-4 
score. Like the HEV IgG and Fib-4 analysis, the IgM and ALT analysis found gender, 
liver disease, and alcohol consumption to be associated with higher levels of ALT. Major 
differences were that age was not influential, but race was; with Hispanics having 
substantially higher ALT score than non-Hispanic whites, and non-Hispanic blacks 
having lower ALT than non-Hispanic whites. 
 
Conclusions 
Paper 1 – Seroprevalence 
Overall, this project has found that HEV infections are not rare in the United States. 
While initial estimates of ~21% from 1988-1994 sera overestimated seroprevalence, 
there still seemed to be a large decline to 16% and then 6% between 1988-1994 and 
2009. However, between 2009 and 2016, seroprevalence estimates has remained stable 
at ~6%. This is indicative that sometime between 1994 and 2009, there was truly a 
dramatic trend downward that stabilized at 6%. 
There were several demographic risk factors identified in this study, but no risk factors 
linked to transmission itself. We found that older people were more likely to have been 
infected and racial patterns such as non-Hispanic Asians to have over twice the average 
national seroprevalence. This does not necessarily mean they are at higher risk of 
contracting HEV in the U.S. especially because the association became non-significant 
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when accounting for people born outside the United States.  Beyond non-Hispanic 
Asians specifically, we found evidence that a significant number of the people testing 
positive for HEV infection possibly acquired it abroad. In the case of Mexican Americans, 
we found those born outside the United States had a higher than national average 
seroprevalence – as expected – however, Mexican Americans in general had a lower 
than average seroprevalence. The reason for this is unknown but may be due to how 
cultural practices or geographic population distribution intersect with transmission 
pathways. 
Paper 2 – Test Comparison 
In both the seroprevalence estimates and the agreement statistics, there appear to be 
significant differences between the tests used to ascertain prior HEV infection. However, 
these assays were developed as clinical tests, not epidemiologic screening tools, and 
prior studies have found that when used in a clinical context, the tests are more 
comparable. The likely reason for this is that the general population has a far lower 
seroprevalence than people suspected to have HEV and the tests have been designed 
with sensitivity in mind. The poor performance in a low seroprevalence population is 
particularly indicative of poor specificity; in particular, it can be inferred that tests with 
generally low specificity as compared to the other tests value sensitivity more than 
specificity. Of the investigated tests, the DS-EIA consistently had the highest specificity 
when compared against other tests; this, combined with the low prevalence of HEV in 
the U.S. means DS-EIA would have the strongest positive predictive value, and may be 
the most appropriate in a population context. 
Paper 3 – Subclinical Manifestations 
This dissertation also found some evidence that subclinical HEV infections could 
contribute to liver fibrosis, but the associations were tenuous. There was no evidence of 
liver inflammation in persons recently infected with HEV. However, most of the cases 
detected in this study would likely be asymptomatic, so this finding does not contradict 
previous studies showing inflammation in patients with clinical cases of HEV infection. 
Overall, it appears that the impact of asymptomatic HEV infection and HEV infection in 
the general population is minimal, with only a slight, technical increase in risk found in 




Public Health Implications 
Hepatitis E was not found to have a large public health impact in the United States. 
While the seroprevalence was non-trivial, we found little to no health impact to those 
infected. This evidence suggests, broad screening programs and vaccination programs 
are not warranted in the United States. This study did find that a significant number of 
people having been infected with HEV likely acquired it overseas, so a patient 
presenting with hepatitis symptoms who have recently been outside of the U.S. should 
be tested for HEV – especially because the genotypes present outside of the U.S. tend 
to be more virulent. 
There are two major caveats: the focus on liver complications and the population 
examined. While HEV is commonly thought to be a virus that damages the liver, some 
research has shown it has a capacity to damage other organs. This study only examined 
the health impacts of HEV infection on the liver; it is possible that HEV in the general 
population has larger extra-hepatic impact than hepatic. This study also does not 
specifically examine the population most at risk for HEV infection complications – 
immunocompromised persons. As chronic HEV infection, HEV reactivation and other 
deleterious effects are primarily in the immunocompromised population, screening this 
population may still be a net benefit, but the tests used in this study rely on an intact 
immune system, so screening would likely need to be done with PCR tests. If HEV 
infection is detected, they should be further screened for liver damage and be 
considered for additional evaluation.  Ribavirin has been shown to be an effective 
treatment in immunocompromised patients as well as those with intact immune systems 
32.   
Research Implications 
While this study found current HEV seroprevalence in the U.S., identified demographic 
trends in HEV seroprevalence, clarified previous inconsistencies in the prevalence of 
HEV in the United States, and examined subclinical hepatic effects, there is still much to 
be learned about HEV infections in general and in the U.S. specifically. More research 
needs to be conducted on infection pathways in the U.S., diagnostic techniques, extra-
hepatic manifestations, and long-term effect of viral infection. 
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This study was unable to find potential pathways for HEV transmission in the United 
States. This study examined water source, shellfish consumption, and blood transfusion. 
The largest potential risk factor that could not be assessed with NHANES with enough 
precision was meat consumption, specifically pork consumption. Finding pathways of 
infection for HEV would allow additional recommendations for those at risk for HEV 
complications. For these reasons, additional studies should examine potential pathways 
of infection of HEV.  
This research also demonstrated that the many tests used to diagnose HEV do not have 
high agreement in an epidemiologic environment although previous studies showed 
mixed results of assay agreement in clinical context. Furthermore, NHANES did not use 
HEV RT-PCR diagnostic techniques on any of the samples. RT-PCR is an increasingly 
used diagnostic technique and has been applied to HEV. A major advantage of RT-PCR 
is the detection of virus itself with evidence of current replication, whereas serological 
assays only detects an immunological response – which continues to linger for a 
variable amount of time after the virus has been cleared. The inconsistencies between 
assays, lack of a gold standard, and new diagnostic tests entering the market all clearly 
demonstrate a need to conduct further research on the diagnostic techniques  
This study did not examine potential extra-hepatic effects of HEV. It is possible that while 
typical symptomatic HEV infection primarily has hepatic effects, asymptomatic HEV 
instead could affect other body systems. In humans, HEV has been shown to impact 
different organs to varying degrees 74 51; with neurological 90, renal, pancreatic and 
hematological manifestations been reported. However, the validity of these associations 
and the overall impact in patients with asymptomatic, acute, and chronic HEV infection 
remains to be clarified. Further research needs to be done to establish the risk of these 
complications in each of these organ groups and infection stages. 
None of these research questions can be adequately answered with the NHANES 
dataset because it does not collect enough data on risk factors, is limited to testing for 
HEV seropositivity with just one ELISA assay, and measure limited outcome variables. 
Due to the subclinical nature of HEV infections, both cohort and cross-sectional studies 
would be economically infeasible unless they were conducted as a component of 
another study that collected sera and included the relevant questions. In the absence of 
this capability, a case-control study would be ideal. A case-control study would be 
resilient against the relatively low incidence of HEV infections and would be able to 
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collect both sera and the data pertaining to infection pathways and routes. However, in 
the United States, HEV is not routinely screened for, sometimes even in the presence of 
otherwise unexplained hepatic disease, so the identification of cases would likely need 
to be done as a part of the study, rather than from a registry.   
 
Final Thoughts 
This study re-enforced previous findings that 1 in 16 people in the U.S. has been 
infected with HEV, but still no clear infection route has been identified. However, these 
findings may be disputed in the future if a similar study is conducted using a different 
serological assay – as another major finding of this study was a significant disagreement 
between different assays. Thus, more research needs to be done to establish a gold 
standard for current and past HEV infections. This study suggested that in the general 
U.S. population, there are few hepatic concerns from HEV manifestations; however, 
there have been studies showing HEV infections causing extra-hepatic effects, so there 
may still be some clinical concerns in the general population not identified in this study. 
Furthermore, it has been well established that HEV infection in immunocompromised 
populations can be chronically damaging. Overall, while this study did not find major 
public health implications in HEV infections, this study is not exhaustive in the identifying 
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Table 1. Comparison of Hepatitis E between Developing Countries and Developed 
Countries 
 Developing Countries Developed Countries 
Transmission Waterborne Foodborne 
Highest Risk for Infection Young Men Middle-Aged Men 
Elevated Mortality Risk in 
Pregnant Women 
Yes No 
Chronic Manifestations No Yes 
Potential for Large 
Outbreaks 
Yes No 
























































2009-2010 6.00% (5.1%, 7.0%) 0.50% (0.3%, 0.8%) 
2011-2012 5.80% (4.6%, 7.0%) 1.60% (1.2%, 2.2%) 
2013-2014 4.60% (3.7%, 6.0%) 0.70% (0.3%, 1.1%) 
2015-2016   8.10% (7.0%, 10.0%) 1.20% (0.9%, 2.2%) 









95% CI Lower 
Estimate 
95% CI Upper 
Estimate 
Age in Years    
Below 20   0.50%   0.32%   0.74% 
20-30   1.33%   0.96%   1.79% 
30-40   2.91%   2.33%   3.59% 
40-50   5.00%   4.05%   6.09% 
50-60   8.08%   6.45%   9.96% 
60-70 14.42%          12.22% 16.84% 
70-80 17.08% 17.08% 17.08% 
Above 80 18.48% 15.88% 21.32% 
Gender    
Male   5.79%   5.27%   6.35% 
Female   6.44%   5.69%   7.25% 
Education    
High School Equiv or 
Above   7.12%   6.44%   7.85% 
Less than High School   8.90%   7.57% 10.37% 
Poverty Index    
Above Poverty Line   6.25%   5.62%   6.93% 
Below Poverty Line   4.71%   3.81%   5.75% 
Race/Ethnicity*    
Non-Hispanic White   6.85%   5.93%   7.86% 
Non-Hispanic Black   3.44%   2.92%   4.03% 
Mexican American   4.37%   3.54%   5.33% 
    Other Hispanic   2.77%   1.97%   3.79% 
Non-Hispanic Asian 12.82% 11.13% 14.67% 
Non-Hispanic Other   4.42%   2.51%   7.14% 
Military Status    
Is/Was in Military   6.21%   4.69%   8.04% 
Never in Military   6.46%   5.78%   7.19% 
Birthplace    
Inside U.S.   5.49%   4.91%   6.12% 
Outside of U.S.   9.37%   8.14% 10.72% 
Years spent in U.S.**    
Less than 5   6.30%   4.52%   8.51% 
5-10   9.06%   6.93% 11.58% 
10-20   8.38%   6.54% 10.54% 
20-30 10.04%   7.65% 12.88% 
More than 30 12.46%   9.81% 15.51% 
*Race/Ethnicity estimate 2011-2016 only because Asian race missing in 2009-2010 
**Years spent in U.S. only assessed in persons born outside of the U.S. 
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Table 5. Summary of Individual Models of HEV infection Risk in U.S. (2009-




95% CI Lower 
Estimate 
95% CI Upper 
Estimate 
Education Level    
High School or Above 1.00 REF REF 
Lower than High School 1.07 0.91 1.25 
Poverty Index    
Above Poverty Level 1.00 REF REF 
Below Poverty Line 1.05 0.88 1.25 
Race*    
Non-Hispanic White 1.00 REF REF 
Non-Hispanic Asian 2.18 1.85 2.57 
Non-Hispanic Black 0.68 0.56 0.82 
Mexican American 1.16 0.94 1.43 
Other Hispanic 0.63 0.46 0.87 
Other 0.95 0.65 1.40 
Military Status    
No 1.00 REF REF 
Yes 0.69 0.53 0.90 
Birthplace    
Born in U.S. 1.00 REF REF 
Born outside of U.S. 1.75 1.49 2.06 
Years in U.S.**    
More than 30 1.00 REF REF 
Less than 5 1.22 0.84 1.76 
5-10 1.65 1.25 2.2 
10-20 1.29 0.98 1.69 
20-30 1.22 0.93 1.60 
Ever Blood Transfusion    
    No 1 REF REF 
    Yes 0.95 0.82 1.09 
Recent Shellfish    
No 1.00 REF REF 
Yes 1.10 0.96 1.25 
Tap Water Source   
Community Supply 1.00 REF REF 
Don't Drink Tap 1.05 0.53 2.08 
Well or rain cistern 1.07 0.79 1.46 
Spring 1.74 0.88 3.46 
*Race/Ethnicity Analysis with 2011-2016 data due to Asian race classification missing 
in 2009-2010 
**Years spent in U.S. only assessed in persons born outside of the U.S. 
72 
 







95% CI Upper 
Estimate 
Intercept 0.01 0.00 0.01 
Age in Years 1.05 1.05 1.05 
Gender       
Female 1 REF REF 
Male 0.94 0.85 1.04 
Race/Ethnicity & Birthplace    
US-Born Non-Hispanic White 1 REF REF 
US-Born Non-Hispanic Black 0.67 0.55 0.82 
US-Born Non-Hispanic Asian 1.04 0.59 1.82 
US-Born Mexican American 0.36 0.23 0.55 
US-Born Other Hispanic 0.45 0.28 0.72 
US Born Other Race 0.86 0.53 1.39 
Foreign-Born Non-Hispanic White 1.41 0.90 2.23 
Foreign-Born Non-Hispanic Black 0.83 0.43 1.62 
Foreign-Born Non-Hispanic Asian 2.34 1.97 2.79 
Foreign-Born Mexican American 1.86 1.45 2.37 
Foreign-Born Other Hispanic 0.71 0.49 1.03 












95% CI Lower 
Estimate 
95% CI Upper 
Estimate 
Intercept 0.00 0.00 0.01 
Age in Years 1.05 1.04 1.05 
Gender    
Female 1.00 REF REF 
Male 0.96 0.86 1.08 
Race/Ethnicity*    
Non-Hispanic White 1.00 REF REF 
Non-Hispanic Black 0.64 0.53 0.77 
Mexican American 0.90 0.73 1.11 
Other Hispanic 0.47 0.35 0.61 
Other 1.15 0.97 1.37 
Birthplace    
Born in US 1.00 REF REF 
Born outside of US 1.85 1.48 2.30 
Tap Water Source    
Community Source 1.00 REF REF 
Don't drink tap water 0.98 0.82 1.18 
Well or rain cistern 1.02 0.77 1.35 
Spring 1.01 0.57 1.78 
Shellfish Consumption    
No 1.00 REF REF 
Yes 1.07 0.94 1.22 
Ever Blood 
Transfusion   
No 1.00 REF REF 
Yes 1.00 0.86 1.16 





Figure 2. NHANES III Sera Subsampling Scheme 
 
 





















































(0.647,0.72) NA NA NA NA NA 
*These were done on a non-random subset of DSI and hence should not be 






Table 9. HEV Seroprevalence in U.S. using Standardization (95% CI) 
  
NHANES III NHANES 2009-2016 
In House EIA 0.209 (0.201, 0.217) NA 
DS-EIA-ANTI-HEV-G 0.162 (0.150, 0.174) 0.058 (0.055, 0.061) 
WANTAI HEV-IgG 
ELISA* 0.629 (0.586, 0.677) NA 
Anti-HEV Western Blot* 0.588 (0.546, 0.636) NA 
*These were done on a non-random subset of DSI and hence should not be 






Table 10. Comparative Sensitivity of HEV Assays from NHANES III 












(95% CI) Sens (95% CI) 








































Table 11. Comparative Specificity of HEV Assays from NHANES III 








Gold Standard Spec (95% CI) 
Spec (95% 
CI) Spec (95% CI) 
Spec (95% 
CI) 
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Western Blot X X X X 
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HEV IgG Positive 
Percent/Mean 
(95% CI) 
HEV IgG Negative 
Percent/Mean (95% 
CI) 
Gender    
Female 













Age (In Years) 
          41.1 (40.5, 
41.6) 
          59.3 (58.3, 
60.2) 
         39.9 (39.3, 
40.4) 
Race/Ethnicity    
Mexican American 
   10.0% (7.8%, 
12.2%) 
     7.9% (5.7%, 
10.1%) 
  10.2% (8.0%, 
12.3%) 
Non-Hispanic Black 
   11.4% (9.6%, 
13.3%) 
        6.4% (5.0%, 
7.8%) 
  11.7% (9.8%, 
13.6%) 
Non-Hispanic White 
 64.3% (60.6%, 
68.0%) 





        8.1% (7.1%, 
9.1%) 
     12.2% (9.9%, 
14.5%) 
       7.8% (6.9%, 
8.8%) 
Other Hispanic 
        6.2% (4.9%, 
7.5%) 
         3.2% (2.3%, 
4.0%) 
       6.4% (5.1%, 
7.7%) 
Body Mass Index 
           27.7 (27.6, 
27.9) 
            29.1 (28.6, 
29.6) 




           2.86 (2.76, 
2.95) 
            3.02 (2.89, 
3.15) 
          2.85 (2.75, 
2.95) 
Hepatitis E IgG 
         6.1% (5.6%, 
6.7%) 100.0% 0.0% 
Hepatitis E IgM 
          1.0% (0.8%, 
1.2%) 
          6.1% (4.3%, 
7.9%) 
        0.7% (0.5%, 
0.8%) 
High Risk Group 
   22.0% (21.2%, 
22.7%) 
    32.4% (29.3%, 
35.4%) 




          1.1% (0.9%, 
1.2%) 
          1.7% (1.0%, 
2.3%) 
        1.0% (0.9%, 
1.2%) 
Has Had Diabetes    
No 
    90.1% (89.6%, 
90.7%) 
    82.3% (80.4%, 
84.1%) 
 90.6% (90.1%, 
91.2%) 
Borderline 
           1.9% (1.6%, 
2.1%) 
          2.8% (1.9%, 
3.8%) 
        1.8% (1.6%, 
2.0%) 
Yes 
            8.0% (7.5%, 
8.5%) 
   14.9% (13.1%, 
16.7%) 





Transfusion    
Don't Know 
            0.9% (0.8%, 
1.1%) 
         1.9% (1.0%, 
2.7%) 
         0.9% (0.8%, 
1.0%) 
No 
     90.2% (89.6%, 
90.7%) 
  81.6% (79.4%, 
83.9%) 
   90.7% (90.2%, 
91.3%) 
Yes 
            8.9% (8.3%, 
9.4%) 
  16.5% (14.3%, 
18.6%) 
          8.4% (7.8%, 
8.9%) 
Ever Liver Condition    
No 
     96.5% (96.2%, 
96.9%) 
   95.1% (93.2%, 
97.0%) 
   96.6% (96.3%, 
97.0%) 
Yes 
            3.4% (3.0%, 
3.7%) 
          4.8% (3.0%, 
6.6%) 
          3.2% (2.9%, 
3.6%) 
Ever Injection Drug 
Use    
No 
     97.7% (97.3%, 
98.1%) 
 98.4% (97.5%, 
99.3%) 
    97.6% (97.2%, 
98.1%) 
Yes 
           2.2% (1.8%, 
2.6%) 
        1.5% (0.6%, 
2.3%) 
           2.3% (1.8%, 
2.7%) 
Average Daily Drink 
             0.59 (0.56, 
0.62) 
          0.64 (0.51, 
0.76) 
              0.59 (0.56, 
0.62) 
Fib4 
             1.06 (1.04, 
1.08) 
          1.56 (1.50, 
1.61) 
              1.03 (1.01, 
1.05) 
NAFLD 
         -2.10 (-2.14, -
2.06) 
      -1.19 (-1.28, -
1.10) 
          -2.16 (-2.20, -
2.13) 
ALT (IU/L) 
             24.8 (24.5, 
25.1) 
          23.8 (23.0, 
24.6) 
              24.8 (24.5, 
25.2) 
Albumin (g/L) 
             43.2 (43.1, 
43.4) 
          42.7 (42.5, 
42.9) 
              43.3 (43.2, 
43.4) 
AST (IU/L) 
             25.6 (25.3, 
25.8) 
          26.0 (25.2, 
26.8) 
              25.5 (25.3, 
25.8) 
Platelet (1k/uL) 
       242.4 (240.9, 
243.9) 
   231.1 (227.4, 
234.9) 








Table 14. Linear Model of ALT and HEV IgM Status in General Population from 
NHANES 2009-2016 








Intercept 20.32 19.22 21.43 
Gender       
Female 0 REF REF 
Male  8.46  7.70  9.21 
Race/Ethnicity       
Non-Hispanic White 0 REF REF 
Non-Hispanic Black -2.07 -2.87 -1.28 
Mexican American  6.48  4.49  8.28 
Other Hispanic  2.97  1.45  4.48 
Other  0.58 -0.58  1.73 
Age InYears -0.01 -0.03  0.01 
IgM Positive       
No 0 REF REF 
Yes  -0.22 -4.17  3.72 
Ever Had Liver 
Condition     
No 0 REF REF 
Yes 9.44  6.90 11.99 
Average Daily Drink  1.24  0.74  1.70 
Diabetes Diagnosis       
No 0 REF REF 
Borderline  0.22 -2.15  2.60 
Yes  0.04  -1.56  1.64 
Ever Injection Drug 
Use       
No 0 REF REF 






Table 15. Linear Model of ALT and Exclusively HEV IgM Status in General 
Population from NHANES 2009-2016 








Intercept 20.33 19.22 21.44 
Gender       
Female 0 REF REF 
Male 8.45 7.70 9.21 
Race/Ethnicity       
Non-Hispanic White 0 REF REF 
Non-Hispanic Black -2.07 -2.86 -1.28 
Mexican American 6.48 4.69 8.28 
Other Hispanic 2.97 1.45 4.49 
Other 0.58 -0.58 1.74 
Age In Years -0.01 -0.03 0.01 
Only IgM Positive       
No 0 REF REF 
Yes -1.11 -5.53 3.32 
Ever Had Liver 
Condition     
No 0 REF REF 
Yes 9.50 6.90 11.99 
Avg Daily Drink 1.22 0.74 1.70 
Diabetes Diagnosis    
No 0 REF REF 
Borderline 0.22 -2.15 2.60 
Yes 0.04 -1.5 1.64 
Ever Injection Drug 
Use    
No 0 REF REF 







Table 16. Risk Ratio Model Liver Fibrosis and HEV IgG status in General 
Population from NHANES 2009-2016 








Intercept 0.00 0.00 0.00 
Gender    
Female 1 REF REF 
Male 1.17 1.05 1.29 
Race/Ethnicity    
Non-Hispanic White 1 REF REF 
Non-Hispanic Black 0.95 0.77 1.19 
Mexican American 0.89 0.80 0.99 
Other Hispanic 0.94 0.84 1.06 
Other 0.95 0.84 1.08 
Age (In Years) 1.08 1.08 1.09 
IgG Positive    
No 1 REF REF 
Yes 1.03 1.01 1.05 
Ever Had Liver 
Condition 
  
No 1 REF REF 
Yes 1.35 1.24 1.46 
Average Daily Drink 1.04 1.02 1.06 
Diabetes Diagnosis    
No 1 REF REF 
Borderline 1.01 0.93 1.09 
Yes 0.98 0.95 1.01 
Ever Injection Drug 
Use 
   
No 1 REF REF 








Table 17. Linear Model of ALT and HEV IgM Status in High Risk Population from 
NHANES 2009-2016 








Intercept 30.36 28.26 32.45 
Gender    
Female 0 REF REF 
Male 6.78 5.40 8.15 
Race/Ethnicity       
Non-Hispanic White 0 REF REF 
Non-Hispanic Black -2.27 -3.56 -0.98 
Mexican American 4.49 2.06 6.92 
Other Hispanic 1.90 -0.64 4.43 
Other 3.10 -2.15 8.35 
Age In Years -0.12 -0.15 -0.08 
IgM Positive       
No 0 REF REF 





Table 18. Risk Ratio Model of Liver Fibrosis and HEV IgG status in High Risk 
Population from NHANES 2009-2016 








Intercept 0.02 0.01 0.02 
Gender    
Female 1 REF REF 
Male 1.05 1.00 1.11 
Race/Ethnicity       
Non-Hispanic White 1 REF REF 
Non-Hispanic Black 1.01 0.96 1.06 
Mexican American 0.92 0.84 1.01 
Other Hispanic 0.95 0.87 1.05 
Other 0.93 0.84 1.04 
Age In Years 1.05 1.05 1.05 
IgG Positive       
No 1 REF REF 
Yes 1.02 0.98 1.06 
 
 
 
 
 
